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ABSTRACT OF THE DISSERTATION
NOVEL NUCLEOSIDE ANALOGUES WITH BASES MODIFIED WITH (βHALO)VINYL SULFONE OR β-KETO SULFONE AS PROBES TO STUDY
RNA/DNA-PROTEINS INTERACTIONS
by
Sk Md Sazzad Hossain Suzol
Florida International University, 2017
Miami, Florida
Professor Stanislaw F. Wnuk, Major Professor
The C-5 modified pyrimidine analogues are well-known anticancer and antiviral
drugs which underscore further development of novel probes to study their physical,
chemical, and biological properties. In my dissertation the syntheses and properties of
(β-halo)vinyl sulfone and/or (β-keto)sulfone analogues of C-5 modified pyrimidine
have been discussed. In the first part of the dissertion, the synthesis of 5-(β-halo)vinyl
sulfones either by transition metal-catalyzed or iodine-mediated halosulfonylation
reaction of 5-acetylene pyrimidine nucleosides have been explored. The novel (βchloro/bromo/iodo)vinyl sulfones efficiently undergo addition-elimination reaction
with different nucleophiles such as thiols, amines, amino acid, peptides to provide (βsubstituted)vinyl sulfone analogues. The rate of these substitution reactions depends on
the nature of halogen atom presents at the β-position and increases with the order of
I ≥ Br > Cl. (β-chloro/bromo/iodo)vinyl sulfones possess exclusively E stereochemistry
while their β-substitued analogues possess either E (for β–thio analogues) or Z (for β–
amino analogue) stereochemistry. It has been observed that the vinylic proton of (β-

v

chloro) or (β-amino)sulfone analogue undergoes exchanges with deuterium in polar
protic deutorated solvents. The antiproliferative activities of those analogues have been
explored and was found that protected 5-(E)-(1-chloro-2-tosylvinyl)-2'-deoxyuridine
inhibited the growth of L1210, CEM and HeLa cells in lower micromolar range.
In the second part of the dissertation the syntheses and reactivities of 5-(β-keto)
sulfone of pyrimidine nucleosides were investigated. Thus, 5-(β-halovinyl)sulfone of
uracil and cytosine nucleosides have been efficiently converted into corresponding 5(β-keto) sulfone analogues by displacement of halogen with ammonia followed by acidcatalyzed hydrolysis of the resulting (β-amino)sulfone analogues. A number of
electrophiles were trapped at the acidic α-carbon of the 5-(β-keto)sulfones by treatment
with electrophiles such as methyl, benzyl, or allyl halide in the presence of base. The 5(α-iodo-β-keto)sulfone analogues of uracil nucleosides have been tested as an
alternative substrates to probe the incorporation of nucleophiles at α-carbon.
In the third part of the dissertation, the synthesis of 5'-phosphates of 5-(β-chloro)
and

5-(β-keto)

sulfones

of

2'-deoxyuridine

and

their

polymerase-catalyzed

incorporation into DNA were evaluated. Thus, 5'-O-phosphorylated analogues have
been efficiently incorporated into the DNA by human DNA repair polymerase (pol β)
or bacterial polymerase (pol I).
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1. INTRODUCTION
1.1. Importance of nucleosides and nucleotides
Nucleosides are the glycosyamines which possess a β-glycosidic bond between the base
and the sugar moiety while nucleotides additionally have one or more phosphate groups at the
sugar moiety. Nucleosides can be converted into nucleotides inside the cell by nucleoside
kinases which are the basic building blocks of deoxyribonucleic acid (DNA) and ribonucleic
acid (RNA). Both DNA and RNA are the source of life in living cells where DNA carries the
message. The discovery of the double helix structure of DNA by Watson and Crick is the
milestone for the development of modern nucleoside and nucleotide chemistry. Both
nucleosides and nucleotides play key roles in DNA and RNA replication which is critical for
cell proliferation. Specific nucleoside transporters transport nucleoside analogues inside the
cells where they are phosphorylated by nucleoside kinases.1,2 The phosphorylated nucleoside
analogues are incorporated into DNA by DNA polymerase catalyzed reaction and thus induce
the termination of chain elongation,3 the accumulation of mutation4-6 as well as apoptosis.7,8
So, through the modification of either the base or sugar moiety, nucleosides can inhibit the
carcinogenic cell proliferation and viral DNA and RNA replication thus captivate attention to
study as a precursor molecule in chemistry and biology.
1.1.1. Nucleoside analogues as anticancer drugs
Both pyrimidine and purine nucleoside analogues serve as potent anticancer drugs. For
example cytarbine contributes to cure amyeloid leukeamia9, while 6-mercaptapurine is
efficacious against acute lymphoblastic leukaemia.10 Gemcitabine, a bifluorinated pyrimidine
nucleoside derivative is very active against haematological malignancy and different solid
tumors.11 So far 14 nucleoside analogues have been approved by the US Food and Drug
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Administration (FDA) for the treatment of cancer which is 10% of the total cancer drugs
available in the market. In addition a couple of nucleoside analogues such as Sapacetabine,12
8-chloro-adenosine,13,14 8-amino adenosine15 are waiting for the approval of FDA.
Table 1. FDA approved anticancer purine and pyrimidine nucleoside analogues16
Drug

Category

Year

6-mercaptopurine (Purinethol)

Purine

1953

5-fluorouracil (Adrucil)

Uracil

1962

6-thioguanine (Lanvis)

Guanine

1966

arabinofuranosylcytosine (Cytarabine)

Cytidine

1969

5-fluoro-2'-deoxyuridine (Floxuridine)

2′-Deoxyuridine

1970

arabinofuranosyl-2-fluoroadenine (Fludarabine)

Purine analogue

1991

2'-deoxycoformycin (Pentostatin)

Adenosine

1991

2-chloro-2'-deoxyadenosine (Cladribine)

2′Deoxyadenosine

1992

2,2-difluoro-2'-deoxycytidine (Gemcitabine)

2′-Deoxycytidine

1996

Cytidine

1998

Cytidine

2004

5-aza-cytidine (Azacitidine)

2′-Deoxyadenosine

2004

O6-methylarabinofuranosyl guanine (Nelarabine)

Guanosine

2005

5-aza-2'-deoxycytidine (Decitabine)

2′-Deoxycytidine

2006

4

N -pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
(Capecitabine)
2'-fluoro-2'-deoxyarabinofuranosyl-2-chloroadenine
(Clofarabine)

1.1.2. Nucleoside analogues as antiviral drugs
Nucleoside analogues are well-known drugs because of their capability to treat a variety of
viral infected patients including Hepatitis C virus (HCV), Hepatitis B virus (HBC), Human
immunodeficiency virus (HIV), Herpes simplex virus (HSV), Varicella zoster virus (VZV),
and Influenza virus. Several 2'-deoxy-2'-fluorocytidine (FdC) derivatives are well-known
anti-HCV compounds such as methylated form of FdC (PSI-6130) can effectively inhibit the
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genotype 1b HCB subgenomic replicon system.17 Mericitabine in combination with pegylated
interferon and ribavirin and or a first –generation protease inhibitor is very active to inhibit
hepatitis C viral replication.18,19 Elvucitabine and Apricitabine are potent inhibitor of human
immunodeficiency viral (HIV) replication.20,21 Festinavir which is also known as BMS986001 is a chemically modified first generation anti-HIV nucleoside analogue stavudine
increased potency and reduced mitochondrial toxicity.22,23 Cyclopropavir which as a
guanosine derivative and structurally related to actyclovir and ganciclovir is active against
many herpesveuses including human cytomegalovirusm human herpesvirus 6A, human
herpesvirus 6B and human herpesvirus 8.24,25 Because of the potency against a wide range of
herpes simplex virus, many protides of cyclopropavir have been synthesized and their
antiviral activities are under investigation.26
Table 2. Antiviral properties of purine and pyrimidine nucleoside analogues27
Drug

Category

Year

5-iodo-2'-deoxyuridine (Idoxuridine

Uridine

1962

5-ethyl-2'-deoxyuridine (Edoxudine)

Thymidine

1969

9-β-D-arabinofuranosyladenine (Vidarabine)

Adenosine

1976

(E)-5-(2-bromovinyl)-2'-deoxyuridine (Brivudine)

Uridine

1980

2-amino-1,9-dihydro-9-[(2hydroxyethoxy)methyl]-6H-purin-6-one

Guanosine

1982

3'-azido-3'-deoxythymidine (Zidovudine)

Thymidine

1987

2',3'-didehydro-2',3'-dideoxythymidine (Stavudine)

Thymidine

1994

2',3'-dideoxy-3'-thiacytidine (Lamivudine)

Cytidine

1998

2',3'-didehydro-2',3'-dideoxythymidine (Stavudine)

Thymidine

2001

4-Hydroxy-3-(hydroxymethyl)-2methylidenecyclopentylguanosine

Thymidine

2005

3

5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3oxathiolan-5-yl]cytosine
Tenofovir disoproxil fumarate, mixture of purine
analogues (Tenofovir)
2'-deoxy-2'-fluoro-2'-methyluridine-5'-phosphate
(Sofosbuvir)

Cytidine

2006

Purine

2008

Thymidine

2013

1.2. 5-Modified pyrimidine nucleosides as reactive probes for bioconjugation
Considering the importance of bioconjugation in medicinal chemistry, chemical biology,
nanotechnology, and material sciences, a considerable amount of effort has been given to
connect new probes of nucleotides with peptides, proteins, and other biomolecule.28 The
bioconjugation strategy enables us to link important modified biomolecules to study chemical
reactions on living cells, which can be crucial to verify the credibility of the anticancer or
antiviral properties of the corresponding compound.29 Bioconjugation is a useful chemical
strategy to study DNA-protein interactions.30 Attachment of reactive functionalities such as
alkyne, alkene, azide, diene, or aldehyde at the base moiety of nucleosides/nucleotides and
their incorporation into DNA offer good programmability to connect the modified DNA with
important biomolecules. These functionalities allowed the modified DNA to tether with other
biomolecules via click chemistry,31 Straudinger ligation,32 Diels-Alder reactions33 etc.
Some of the notable works in bioconjugation have been done by Hocek’s lab who
introduced aldehyde functionality at 5 position of cytidine nucleotide and incorporated them
into DNA and subsequently stained with 2,4-dintrophenyl hydrazine (2,4-DNPH) or
nitrobenzofurazanehydrazine via hydrazone formation.34 He also tethered reactive aldehyde
functional group containing formaryl moieties at 5 position of 2'-deoxycytidine nucleotides
which incorporated via polymerase incorporation. The reactive aldehyde functional group
containing modified DNA was connected with amino acid lysine and peptides.35 Recently Dr.

4

Hocek attached acrylamide and vinylsulfonamide to the 5 position of cytidine triphosphate
and incorporated them into DNA via DNA polymerase. Later he did bioconjugation of these
vinylsulfonamide and acrylamide modified DNA with the tumor-suppressor protein p53.36
These bioconjugations have been taken place via Michael addition reactions where the
modified DNA acts as a Michael acceptor while the protein p53 acts as a Michael donor.

Figure 1. Synthesis of vinylsulfonamide modified DNA by PEX and its cross-linking with
p53 protein36
From all of the examples of bioconjugation, we have been inspired to link the (βhalo)vinyl sulfone modified DNA with amino acid cysteine or proteins having thiol or amine
residues. The 5-modified 2'-deoxypyrimidine nucleoside analogues modified with (βhalo)vinyl sulfone will be an excellent probe in bioconjugate chemistry as they are very
susceptible to different nucleophiles (amine, cysteine etc.) and readily give product via
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addition-elimination reaction. So, our first goal is to synthesize triphosphorylated pyrimidine
nucleoside analogues having (β-halo)vinyl sulfone tethered at 5 postion of the nucloebase to
polymerase catalyzed incorporation into DNA. Next, we want to link this modified DNA with
amino acid cysteine or protein having amino or thiol residue which will efficiently react with
(β-halo)vinyl sulfone through addition-elimination reactions. Note that Michal Hocek did
similar types of bionconjugation via Michael addition reaction but our conjugation is totally
different and occurs via an addition-elimination process. The 5' position of pyrimidine
nucleoside

analogues

modified

with

(β-halo)vinyl

sulfone,

polymerage

mediated

incorporation in DNA and subsequent treatment of this modified DNA with suitable protein
(having amino or thiol residues) will efficiently give bio-conjugated product via additionelimination mechanism. In summary, phosphorylation at 5' position of pyrimidine nucleoside
analogues modified with (β-halo)vinyl sulfone, polymerase mediated incorporation in DNA
and subsequent treatment of this modified DNA with suitable protein will give our desired
bio-conjugated product.
1.3. Overview of (β-halo)vinyl sulfone
The (β-halo)vinyl sulfones having halogen atom at the β-positions of the vinyl functional
group are important precursurs due to their capabilities of serving as synthetic intermediate in
organic chemistry.37,38 Moreover, owing to the presence of reactive functional groups, and
biologically important C-S bond, it has drawn considerable amount of attention to explore
their biological activities.39
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Figure 2. General structure of (β-halo)vinyl sulfones
1.3.1. Synthesis
Terminal alkyne functional group offers unique opportunity to synthesize regio and
stereoselective (β-halo)vinyl sulfone.40 The Eiichi Nakamura group developed Iron-catalyzed
and phosphine ligand-mediated regio and stereoselective chlorosulfonylation reaction. Thus,
treatment of terminal alkyne substrate A with aryl sulfonyl chloride in the presence of iron (II)
acetate and tri(p-tolyl)phosphine and affords (E)-(β-chloro)vinyl sulfone B with excellent
yield (Scheme 1).41

Scheme 1. Synthesis of (E)-(β-chloro)vinyl sulfone analogue from aryl acetylene using
aryl sulfonyl chloride by Eiichi Nakamura’s group
Sulfonyl hydrazide is a well-known source of sulfonyl moiety and widely used reagent
during the halovinylsulfonylation reaction.42 Xiangsheng Xu’s group developed transition
metal catalyzd regio and stereoselective halosulfonylation reaction to synthesize (E)-(βchloro/bromo)vinyl sulfone B by the treatment of phenyl acetylene A with p-tolyl sulfonyl
hydrazide in the presence of iron(III) halides and TBHP afford the halovinyl sulfone B
(Scheme 2).43
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Scheme 2. Synthesis of (E)-(β-chloro/bromo)vinyl sulfone by transition metal catalyzed
halosulfonylation reaction by Xiangseng Xu’s group
The plausible mechanism of the reaction can be explained by the interaction of tertiary
butyl hydroperoxide with iron(III) halide generates tertiary butyl peroxide radical I (Scheme
3). The resulting peroxide radical generates tosyl radical III from tosyl hydrazide through the
removal of nitrogen gas. Attack on the alkyne group by the reactive tosyl radical and
subsequent interaction with iron (III) halide generates regio and stereoselective products (E)β-chloro/bromovinyl sulfone IV (Scheme 3).

Scheme 3. Plausible mechanism of iron(III) halide-mediated halosulfonylation reactions
to afford (E)-β-(chloro/bromo)vinyl sulfones 43
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Xiaoqing Li’s group successfully synthesized (E)-(β-iodo)vinyl sulfone using I2 instead of
iron halides44 as depicted below in Scheme 4. In this reaction interaction of tertiary butyl
hydroxyl radical with tosyl hydrazide generates tosyl radical. Subsequent interaction of tosyl
radical and iodine with alkyne moiety gives (E)-(β-iodo)vinyl sulfone (Scheme 4).

Scheme 4. Synthesis of (E)-(β-iodo)vinyl sulfone via iodine mediated halosulfonylated
reaction by Xiaoqing Li’s group
Treatment of terminal alkyne probes with sodium salt of p-toluene sulfinic acid and iodine
in the presence of sodium acetate afford (E)-(β-iodo)vinyl sulfone as shown in Scheme 5.45

Scheme 5. Synthesis of (E)-(β-iodo)vinyl sulfone using sodium salt of p-toluenesulfinic
acid
N-halosuccinimide (NXS) promoted halosulfonylation of terminal alkyne give (E)-(βbromo/iodo)vinyl sulfones. Treatment of aryl acetyle A with sodium tosylate and N-halo
succinamides (NXS) affords E)-(β-bromo/iodo)vinyl sulfones B as depicted in Scheme 6.46
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Scheme 6. Synthesis of (E)-(β-bromo/iodo)vinyl sulfones via N-bromo/iodo succinamide
mediated halosulfonylation reaction
The plausible mechanism of the reaction can be explained by the formation of the iodide
radical I and succinamide radical by the hemolytic cleavage of N-I bond of NIS in the
initiating step (Scheme 6). Later, tosyl radical II is formed by single electron transfer with the
help of succinamide radical and subsequent regio and stereoselective interaction of these tosyl
radical II and iodide radical I with the terminal alkyne moiety gives (E)-β-iodovinylsulfone
compound III (Scheme 7).

Scheme 7. Plausible mechanism of NIS promoted iodosulfonylation of aryl alkynes44
Iodine and di-tert-butyl peroxide (DTBP) promototed difunctionalization of terminal
alkyne A with sodium benzene sulfinates afforded (E)-β-iodovinylsulfone B with excellent
yield (Scheme 8).47
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Scheme 8. Synthesis of (E)-β-iodovinylsulfone via iodine and DTBP promoted reaction
by Zhao et al.
1.3.2. Biological activity
As vinyl sulfones are organosulfur compounds, the investigation of their biological
activities is always fascinating to the medicinal chemists and biologists. Research shows that
certain type of vinyl sulfone inhibits the replication of human immunodeficiency syndrome
virus type 1 (HIV-1).48 Vinyl sulfones also inhibit the protein degrading enzyme cathepsins L
and B.49 It has been also reported that vinyl sulfones inhibits the activities of cysteine protease
by binding the thiol residue of the enzymes via Michael addition reaction.50
1.4. Overview of β-keto sulfone
The β-keto sulfones also known as 2-oxo-sulfones is a class of organosulfur compound
having active methylene group at the α-position and carbonyl group at the β-position serves as
a versatile synthetic site that can be used to synthesize different classes of organic
compounds.51 Important natural products have been synthesized where β-keto sulfones acts a
structural feature of the target substrate. In addition, certain types of β-keto sulfones exhibit
important biological activities. Considering these diverse applicability, β-keto sulfones have
drawn significant attention in chemistry in last few decades and occupied major parts in
organosulfur chemistry.52
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Figure 3. General structure of (β-keto)sulfone
1.4.1. Synthesis
β-Keto sulfones have been synthesized from various precursor molecules by using a wide
varieties of reagents.53 Treatment of arylmethyl sulfone A with Grignard reagents generates
arylsulfonyl methylene anion which attack at the carbonyl carbon of prop-2-ynals to give βhydroxy sulfones B. Oxidation of these β-hydroxy sulfones by PCC give β-keto sulfones C
with alkyne moiety at the carbonyl group (Scheme 9).54

Scheme 9. Synthesis of β-keto sulfones with alkyne moiety at the carbonyl carbon
Treatment of 4-hydroxy-5-acyl[2.2]paracyclophane A with NaH and triflic anhydride or
nonafluorobutanesulfonyl fluoride gives chiral[2.2]paracyclophane derivatives of β-keto
sulfone B (Scheme 10) which is a potential ligand for asymmetric catalysis.55

Scheme 10. Synthesis of β-keto sulfone with paracyclophane moiety
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The β-keto sulfone moiety attached at 3' position of thymidine analogue has been
reported.56 Treatment of the allene sulfone A with piperidine at rt gives enamine sulfone
intermediate B which convert to the β-keto sulfone C by hydrolysis (Scheme 11).

Scheme 11. Synthesis of β-keto sulfone from sulfonyl allene attached at 3' postion of 2'deoxythymidine nucleoside
The β-keto sulfone has been synthesized from aliphatic or aromatic alkenes by IBX/I2
mediated reactions with sodium arene sulfinates.57 Treatment of the alkene substrates A with
sodium salt of p-toluenesulfinic acid efficiently affords the β-keto sulfone B (Scheme 12).

Scheme 12. Synthesis of β-keto sulfone from alkene via IBX/I2 mediated reaction
Terminal alkyne is a convenient functional group for the synthesis of β-keto sulfone.
Different research groups have synthesized β-keto sulfones reacting terminal alkyne probes
with sulfonyl moiety containing precursors.
Hua’s group successfully synthesized β-keto sulfones B by reacting aryl/heteroaryl
acetylene substrates A with sulfonyl chloride and water in the presence of catalytic amount of
p-toluenesulfonic acid as depicted in scheme 13.58
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Scheme 13. Synthesis of β-keto sulfones by p-toluenesulfonic acid catalyzed reaction
The β-keto sulfones anologues B from acid sensitive acetylene precursors A have been
synthesized using sodium salt of p-toluenesulfinic acid as shown in scheme 14. In this
sulfonylation reaction nitroethane is used as solvent.59

Scheme 14. Synthesis of β-keto sulfones from acid sensitive acetylene precursors
Lei’s group developed dioxygen triggered oxidative difunctionalization of terminal
alkyne A gives β-keto sulfones B from good to excellent yield (Scheme 15).53 In this reaction
pyridine acts a base and prevents atom transfer radical addition (ATRA) process to afford βketo sulfone instead of vinyl sulfone.

Scheme 15. Synthesis of β-keto sulfones via pyridine catalyzed dioxygen triggered
oxidative radical process
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Scheme 16. Mechanism of synthesis of aryl (β-keto)sulfone via pyridine catalyzed
dioxygen triggered oxidative radical reaction
The mechanism of this reaction can be explained as depicted in Scheme 16 which involves
generation of the more stable tosyl radical III from the interaction of p-toluene sulfinic acid
with pyridine followed by oxygen molecule. Interaction of the aryl acetylene with p-toluene
sulfonyl radical followed by molecular oxygen gives peroxy type radical V. Single electron
transfer and protonation gives β-peroxyvinyl sulfone intermediate VII. Subsequent oxygen
abstraction and tautomerization afford β-keto sulfone IX.
1.4.2. Selected reactions of β-keto sulfones
The β-keto sulfones have two reactive centers which are active methylene group and
carbonyl group. So, the reactivity β-keto sulfones can be described by the reactions of each of
these two groups separately or the interplay of these reactive groups. As the position of the
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methylene group is in between two electron withdrawing groups which are carbonyl group
and sulfonyl moiety, the proton of the methylene group is significantly acidic (pKa = 9-10).60
β-Keto sulfones undergoes a base promoted Knoevenagel type of reaction to afford
sulfonyl substituted vinyl ketone derivatives as shown in Scheme 17. Thus treatment of
benzyl sulfonyl ethan-2-one A with aryl aldehydes gives (E)-α-benzylsulfonyl chalcone
derivatives B which possess antiproliferative activity.61

Scheme 17. Knoevengal condensation of β-keto sulfones to afford (E)-α-benzylsulfonyl
chalcone derivatives
Palladium catalyzed allylic alkylation of phenylsulfonyl acetophenone A with either
methyl phenyl acetylene B,62 or phenyl allene C,63 or cinnamic alcohol D,64,65 gives
corresponding highly E-stereoselective α-monoallylated product E as depicted in Scheme 18
with excellent yield.

Scheme 18. Pd-catalyzed allylic alkylation of phenylsulfonyl acetophenone for the
synthesis of E-stereoselective α-monoallylated β-keto sulfone
The α-arylated analogue of β-keto sulfone have been synthesized via direct arylation
reaction as demonstrated in Scheme 19. Thus, palladium catalyzed reaction of phenylsulfonyl
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acetophenone A with aryl bromide in the presence of NaH affords α-arylated product B with
moderate yield.66

Scheme 19. Pd-catalyzed arylation at α-position of phenylsulfonyl acetophenone
Treatment of 1-(4-methylsulfonyl)propane-2-ones A with 1-alkylpyrrolidine-2-thione
methyl iodide salts in the presence of triethylamine; condensation product β-sulfonyl
substituted enamines B are obtained as single E isomer as depicted in Scheme 20.67

Scheme 20. Alkylation of β-keto sulfones with 1-alkylpyrrolidine-2-thione methyl iodide
salts for the synthesis of β-sulfonyl substituted enamines
When of β-keto sulfones A are treated with N-[1-acetoxy-2,22-trichloro)ethyl] urea in the
sodium hydride, trichlorosubstituted oxoalkyl ureas B are obtained. Subsequent treatment of
these oxoalkyl urea products B with para-toluenesulfonic acid give arylsulfonyl-substituted
tetrahydropyrimidin-2(1H)-ones C as shown in Scheme 21.68
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Scheme 21. Alkylation of β-keto sulfones with N-[1-acetoxy-2,22-trichloro)ethyl] urea to
afford arylsulfonyl-substituted tetrahydropyrimidin-2(1H)-ones
Treatment of nonaflyl acetone A with β-chloroethyl isocyanate in the presence of triethyl
amine as base affords corresponding 1,3-oxazolidine B as shown in Scheme 22. In this
reaction triethyl amine deprotonates at the α-carbon of A and subsequent electrophilic attacks
at the isocyanate carbon followed by cyclization and tautomerization gives 1,3-oxazolidine
product B.69

Scheme 22. Synthesis of 1,3-oxazolidine by the reaction of nonaflyl acetone with βchloroethyl isocyanate
α-Diazo β-keto sulfones B are synthesized by treating correspoding β-keto sulfones A with
different sources of diazo group such asTsN3,70 TfN3,71 NfN3,72 I(CF2)2O(CF2)2SO2N3,73 and
ionic-liquid supported sulfonyl azide as depicted in Scheme 23.74
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Scheme 23. Synthesis of α-diazo β-keto sulfones
Treatment of p-toluene sulfonyl acetophenone A with potassium halide and hydrogen
peroxide in acetic acid gives α-monohalogenated product B with high yield where potassium
halides are the source of halogen atoms. Subsequent treatment of these monohalogenated
products B with SO2Cl2 or Br2 in the presence of triethylamine give α,α-dihalogenated
products C as demonstrated in Scheme 24.75

Scheme 24. Chemoselective α-mono and di-halogenation at the α-carbon of β-keto
sulfones
The α-iodo β-keto sulfone B can be prepared efficiently by treating corresponding β-keto
sulfones A either with iodine monochloride in acetic acid,76 or molecular iodine in aqueous
acidic hydrogen peroxide as shown in Scehme 25.77

Scheme 25. Synthesis of α-Iodo β-keto sulfone using iodine monochloride or iodine
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Treatment of β-keto sulfones A with [hydroxyl(tosyloxy)iodo] benzene affords to αtosyloxy substituted β-keto sulfones B from very good to excellent yields as depicted in
Scheme 26.78 No solvent is required in this reaction.

Scheme 26. Synthesis of α-tosyloxy β-keto sulfone via solvent free reaction
Treatment of β-keto sulfone A with formalin, and thiol or thiophenol in water gives
Mannich type thiesters B in good to excellent yield (Scheme 27).79 In this reaction first β-keto
sulfones interact with formaldehyde to give α-methylene β-keto sulfones through a
Knoevangal type reaction. Later the intermediate is attacked by thiol and affords the product
via a Michael addition reaction.

Scheme 27. Incorporation of methylthiol moieties at α- position of β-keto sulfones by
Mannich type reaction
Treatment of methyl sulfonyl A acetone with triflic acid or methanesulfonic acid affords (E)
β-ferrocenyl-α,β unsaturated sulfone B via Friedel-Crafts type reaction as depicted in Scheme
28.80
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Scheme 28. Synthesis of (E) β-ferrocenyl-α,β-unsaturated sulfone via Friedel-Crafts type
reaction
Treatment β-keto sulfone A with hydroxyl amine under reflux in ethanol afford β-hydroxy
sulfone B as demonstrated in Scheme 29.81

Corey-Bakshi-Shibata (CBS) catalyzed asymmetric reduction of β-keto sulfones A with
N-ethyl-N-isopropylaniline-borane complex give optically active β-hydroxy sulfones with
excellent enatiometric excess (ee) as shown in Scheme 30.82

Scheme 29. Asymmetric borane reduction of β-keto sulfones for convertion into βhydroxy sulfones
When β-keto sulfone A is treated with aryl azide in the presence of sodium methoxide, Naryl substituted 1H-1,2,3-trizoles B are afforded from good to excellent yield via base
catalyzed Dimroth reaction (Scheme 31).83
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Scheme 30. Synthesis of N-substituted triazoles from β-keto sulfones via base catalyzed
Dimroth reaction

The reaction of β-keto sulfones A with arylazide in the presence of pyrrolidine as ograno
catalyst affords 4-sulfonyl 1,2,3-triazoles B from good to excellent yields as depicted in
Scheme 32.84 In this reaction pyrrolidine forms enamine with the β-keto moiety which played
the key role for the success of this reaction.

Scheme 31. Synthesis of N-substituted triazoles from β-keto sulfones using pyrolidine as
organo catalyst
1.4.3. Biological activity
The β-keto sulfone contains biologically important sulfonyl moiety which captivates
attention of the pharmaceutical chemist to investigates their pharmacological properties.
Research shows that certain types of (β-keto) sulfones are potent and selective inhibitors of
11β-hydroxysteroiddehydrogenase type 1 (11β-HSD1).85 In addition the (β-keto) sulfones are
active against pernicious microorganism86 and cyclic (β-keto) sulfones also exhibit fungicidal
activities.87
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1.5. Short overview of prodrugs
Prodrugs are the compounds which are metabolized after entering into the cell of the body
to act as drugs.88 The chemical modification of a pharmacologically active agent that must
undergo transformation to release the active drug after entering into the cell is a well known
and

convenient

strategy

to

enhance

the

physiochemical,

biopharmaceutical

or

pharmacokinetic properties of pharmacologically potent compounds.89-92 By designing and
synthesizing prodrugs different parameters such as poor cell permeability, low aqueous
solubility, chemical instability, insuffient oral absorption, rapid pre-systemic metabolism etc.
can be overcome.92,93 In short, prodrugs enhance the absorbtion, distribution, metabolization,
and excretion (ADME) properties of drugs.94 Currently 5-7% of approved drugs can be sorted
out as prodrugs and in 2001-02 about 15% of new drugs were approved as prodrugs.95

Scheme 32. General representation of prodrug concept96
Some common functional groups which are convenient to design prodrugs are carboxylic,
hydroxyl, amine, phosphate/phosphonate, and carbonyl group. These groups can be converted
into esters, carbonates, carbamates, amides, phosphates, and oximes to obtain the
corresponding prodrugs.96 In addition thiols can be converted into thioethers,97 or thioesters98
whereas amine can be converted into imines,99,100 and N-Mannich bases101 as the prodrug
synthetic approach.

23

1.5.1. Prodrug of nucleoside analogues
One of the convenient and effective methods used to synthesize nucleoside prodrugs is the
incorporation of different liphophilic groups either at the base moieties or at the sugar
moieties via acylation or an alkylation reaction to improve cell permeability to the drug.
Gemcitabine is a well-known anticancer drug which is widely used to treat breast cancer,
pancreatic cancer, bladder cancer, lung cancer, and others.102 However, research shows that
significant amount of gemcitabine converts into corresponding uridine analogues in the cell as
a result of the deamination by the cytidine deaminase enzyme.103 4-N-Alkonylation of
gemcitabine can significantly reduce the extent of deamination process and exhibit better
efficiency.104 On the basis of the finding 4-N acylated produg of gemcitabine LY2334737 has
been developed (Figure 4).105,106

Figure 4. 5'-Acylated CP-4126 (A), 4-N-acylated prodrug LY2334737 (B) of Gemcitabine
and Capecitabine (C) prodrug of 5-fluorouracil
The 5'-acylated gemcitabine analogues which is also known as CP-4126 is a well-known
prodrug (Figure 4).107 The lipophilic alkyl long chain enhances the cell permeability of the
original drug gemcitabine. After entering into the cell the prodrug converts into original drug
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gemcitabine by the esterase enzyme.108 Capecitabine is a prodrug of 5-fluorouracil which is
widely used for the treatment of breast cancer, gastric cancer, and colorectal cancer.109,110
Mericitabine which is also known as RG7128 is an antiviral prodrug of PSI-6130 and used
for the treatment of hepatitis C virus infected patients as a combination therapy with other
antiviral drugs (Figure 5).111 The drug acts by inhibiting NS5B RNA polymerase, a primary
transcript RNA.17

Figure 5. PSI 6130 and its prodrug mericitabine (RG7128)
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2. RESEARCH OBJECTIVES
My first research objective was the synthesis of 5-(1-halo-2-tosylvinyl)pyrimidine
nucleosides (A). Recently, (β-halo)vinyl sulfone analogues gained considerable amount of
attention because of their reactivity and important biological activities. As (β-halo)vinyl
sulfones possess reactive halovinyl sulfonyl moiety along with electronegative halogen atom
at the β-position, I thought it would be interesting to synthesize nucleoside analogues
modified with (β-halo)vinyl sulfone and exploring their reactivities and biological properties.
To get access to 5-(β-chloro/bromo)vinyl sulfones (A) I explored transition-metal catalyzed
halovinylsulfonylation of 5-alkynyl uracil and cytosine nucleosides with p-toluenesulfonyl
hydrazine in the presence of tert-butyl hydrogen peroxide. The synthesis of 5-(β-iodo)vinyl
sulfones (A) would be attempted via N-iodosuccinamide mediated halosulfonylation reactions
of the 5-alkynyl uracil and cytosine nucleosides with sodium salt of sulfinic acid.
The typical reaction of the unsubstituted vinyl sulfone with nucleophiles occurs via the
Michael addition reactions. As (β-halo)vinyl sulfone possesses halogen atom at the β-position,
it would be fascinating to explore these type of reactions with the (β-halo)vinyl sulfone. So, I
was planning to explore reactivity of the novel (β-halo)vinyl sulfones with different
nucleophiles i.e., thiolates, amines, amino acid to observe whether it underwent a Michael
addition

or

conjugated

addition-elimination

reaction

to

give

5-(1-substituted-2-

tosylvinyl)pyrimidine nucleosides (B). I was also eager to investigate the feasibility of
bioconjugation of these novel halovinyl sulfone analogues by reacting them with
biomolecules such as tripeptide L-glutathione. The (β-chloro/bromo/iodo)vinyl sulfones
would be prepared to study the mechanism of the conjugated addition-elimination reactions
employing kinetic and synthetic approaches. Since (β-halo)vinyl sulfones as well as their
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products of the addition-elimination reactions with nucleophiles are trisubstituted alkenes, the
stereochemistry at the double bond of these novel pyrimidine-based 5-(β-halo)vinyl sulfones
will be established using advanced 2D-NMR techniques and single X-ray crystallographic
method. Moreover, since 5-modified pyrimidine nucleosides have been demonstrated to
possess antiviral and antiproliferative properties, I would explore the biological properties of
these novel (β-halo)vinyl sulfone in various viral (e.g. herplex simplex virus, human
cytomegalovirus, parafluenza virus) and cancer (e.g. murine leukemia, human T-lymphocyte,
human cervix carcinoma) cells. I was also planning to investigate if changing the polarity of
the (β-halo)vinyl sulfone analogues by incorporating different liphophilic alkyl groups (as an
carboxylic esters) at the sugar moiety would increase their antproliferative properties.

Figure 6. General structure of 5-modified pyrimidine nucleoside analogues
My second research objective was the synthesis of novel 5-(β-keto)sulfone analogues of
pyrimidine nucleoside (C) and exploring their reactivity at the α-carbon of these sulfones.
Synthesis of these novel (β-keto)sulfone analogues would be attempted

by di-oxygen

triggered oxidative radical reaction of the 5-ethynyl pyrimidine nucleosides with ptoluenesulfinic acid in the presence of pyridine and oxygen. Alternatively the (β-halo)vinyl
sulfone analogues would be converted into corresponding β-keto sulfone analogues by
applying one-pot synthetic protocol which would involve conversion of the (β-halo)vinyl
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sulfone into the corresponding (β-amino)vinyl sulfone followed by acid hydrolysis of the
latter intermediate into (β-keto)sulfone will be also developed. Since the α-carbon of 5-(βketo)sulfones C possess acidic protons, I would explore further modification of these novel
probes. My ultimate goal was to verify the feasibility of the reactivity at the α-carbon of βketo sulfone analogues with different electrophiles and possibly nucleophiles and finally
demonstrate the feasibility of the bioconjugation of the 5-(β-keto)sulfone modified DNA with
proteins.
My third and final research objective was to incorporate the novel 5-(β-chloro)vinyl and 5(β-keto)sulfone-2'-deoxyuridine triphosphatesinto DNA so that study of DNA-proteins
interactions under the physiological conditions could be explored. Thus, Yoshikawa
phosphorylation of 5-(β-chloro)vinyl or 5-(β-keto) sulfones followed by coupling of the
resulting

5'-O-monophosphate

with

ammonium

pyrophosphate

should

afford

the

corresponding 5'-O-triphosphates. These novel 5-modified 2'-deoxyuridine nucleotides will be
attempted to be incorporated

into DNA fragments by polymerase-catalyzed reaction. If

successful, I was planning to investigate bioconjugation of these active probes with tripeptide
L-glutathione. My final goal was to explore bioconjugation of such modified DNA with
transcription factors such as c-Myc protein which is rich in nucleophilic thiol (cysteine)
residues. If successful, further study might uncover critical information of the role of this
protein in gene expression and DNA replication.
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3. RESULTS AND DISCUSSIONS
3.1. Chemistry of (E)-5-(1-halo-2-tosylvinyl)pyrimidine nucleosides
3.1.1. Synthesis of (E)-5-(1-chloro/bromo/iodo-2-tosylvinyl)uracil nucleosides
General approaches for the synthesis of targeted 5-modified pyrimidine nucleosides
involve investigation of halosulfonylation reactions with the nucleoside-derived terminal
alkynes. Thus, in the first step a reactive acetylene group was incorporated at C5-position of
the uracil nucleosides which involved highly efficient Sonogashira coupling of 5-iodo uracil
nucleoside analogues following Robin’s procedure112 followed by sequential deprotection of
the protecting groups (Scheme 34).

Scheme 33. Incorporation of reactive acetylene group at 5 position of uracil nucleosides
Iron (III) chloride mediated and TBHP

promoted regio and stereoselective

chlorosulfonylation reaction of protected 5-ethynyluridine 5 gave a single E isomer of 2',3',5'tri-O-acetyl-5-(1-chloro-2-tosylvinyl)uridine (8) with 68% yield. Analogous treatment of
protected

2'-deoxyuridine

4

afforded

3',5'-di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-

deoxyuridine (9) with 76% yield. Treatment of 5-ethynyluridine 7 with p-toluenesulfonyl
hydrazide and iron(III) chloride in the presence of tertiary butyl hydrogenperoxide gave (E)-5(1-chloro-2-tosylvinyl)uridine 10 with 59% yield. Analogous treatment of 6 in the same
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condition gave (E)-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (9) with 90% yield (Scheme
35).90

Scheme 34. Synthesis of (E)-5-(1-chloro/bromo-2-tosylvinyl)uracil nucleosides via iron
catalyzed halosulfonylation reaction
Treatment of 5-ethynyluridine 7 with p-toluenesulfonyl hydrazide and iron(III) bromide in
the presence of tertiary butyl hydrogenperoxide gave (E)-5-(1-bromo-2-tosylvinyl)uridine 11
with 41% yield. The structure of 8-11 was determined by using NMR techniques and the E
stereochemistry was established based on literature report and analysis from X-ray
crystallography as described in Section 3.1.3.2.
The 5-(1-iodo-2-tosylvinyl)uracil nucleoside analogues were synthesized by NIS
promoted halosulfonylation reaction with 5-ethynyl uracil nucleosides and sodium salt of ptoluenesulfinic acid as depicted in Scheme 36.
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Scheme 35. Synthesis of (E)-5-(1-iodo-2-tosylvinyl)uracil nucleosides via NIS promoted
halosulfonylation reaction
Thus treatment of 5-ethynyluridine 7 with sodium salt of p-toluenesulfinic acid gave (E)5-(1-iodo-2-tosylvinyl)uridine 12 with 42% yield. The structure of the compound was
established by the applying different NMR techniques and mass was determined by using high
resolution mass spectrometry. In 1H NMR 12 has vinylic proton peak at 7.72 ppm while the
vinylic carbon peaks appeared at 105.5 ppm.s
3.1.2. Synthesis of (E)-5-(1-chloro/bromo/iodo-2-tosylvinyl)cytosine nucleosides
The β-halo sulfonylation reaction was also extended to cytosine nucleoside. An acetylene
functional group at the C5-position offers a convenient way to synthesize 5-(β-chlorovinyl)
sulfone of cytidine or 2'-deoxycytidine nucleosides. The acetylene moiety was efficiently
incorporated at C5- position of these nucleosides via an acetyl protection at the sugar moiety,
iodination at 5 position, Sonogashira coupling, silyl deprotection (Scheme 37).113

Scheme 36. Synthesis of acetyl protected 5-ethynylcytidine and 2'-deoxycytidine
analogues
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Thus, treatment of 5 ethynyl analogue 17 with tosyl hydrazide in the presence of iron (III)
chloride and tertiary butyl hydrogen peroxide gave (β-chloro)vinyl sulfone analogue 19 with
68% yield. Analogous treatment of 18 with tosyl hydrazide in the similar reaction condition
gave 20 with 60% yield (Scheme 38).

Scheme 37. Synthesis of (E)-β-chlorovinyl sulfone of protected cytidine and 2'deoxycytidine nucleosides
The structure of the compounds 19 and 20 were established by applying different NMR
techniques such as 1H, COSY, HMQC, DEPT-135, and 13C. The exact mass was determined
by applying MALDI-TOF mass spectrometry. In proton NMR vinyl peak of 19 and 20 were
obtained at 7.67 and 7.61 ppm respectively. For both 19 and 20 methyl peak of tosyl group
was observed at 2.40 ppm while the aromatic peaks were observed in between 7.00 to 8.00
ppm. In

13

C NMR the vinyl peak of 19 and 20 was observed at 137.0, and 138.0 ppm

respectively while the methyl carbon peak of tosyl group were appeared at 21.0, and 21.8
ppm. Other aromatic peaks of the tosyl group were observed from 125 to 145 ppm. In addition
a characteristics β-carbon peak was observed at 143.0, and 139.5 ppm respectively. In mass
spectrum the characteristics isotopic pattern of one chlorine atom (peak intensity 3:1) was
observed. Finally, the experimental mass value [M + H]+ 526.1048 and 583.1025 confirmed
the successful synthesis of 19 and 20.
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3.1.3. Addition-elimination reactions of (E)-5-(1-halo-2-tosylvinyl)pyrimidine nucleosides
with nucleophiles
The reactivity of the (β-halo)vinyl sulfones of uracil and cytosine nucleosides was studied
in details, and it was observed that they react efficiently with different nucleophiles such as
amines, thiols, amino acid etc. through addition-elimination process to give the substituted
products from moderate to good yield.

Scheme 38. Displacement of halogen atoms of uracil nucleosides by thiolates and amino
acid to afford analogues with retention of configuration
Treatment of 9 with propane thiol in the presence of triethyl amine afforded propanethio
substituted analogue 26 with 73% yield. Analogous treatment of 10 with propane thiol in the
presence of triethyl amine gave 27 with 75% yield (Scheme 39). Treatment of 9 with
important amino acid derivative L-cysteine ethyl ester hydrogen chloride in the presence of
triethyl amine afforded 28 as a 85/15 E/Z mixture and the yield was 60%. Analogous
treatment of 10 with amino acid derivative L-cysteine ethyl ester hydrogen chloride afforded
29 as a 85/15 E/Z mixture and the yield was 56% (Scheme 39).
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The addition-elimination reaction of chlorovinyl sulfone analogue 9 was extended with
well-known biomolecule and antioxidant L-glutathione. It is noteworithy to mention that
glutathione is a tripeptide and thus can serve as a model compound to study bioconjugation
with protein.
Thus, treatment of chlorovinyl sulfone analogue 9 with L-glutathione in the presence of
triethylamine in mixed solvent (water and methanol) afforded glutathione incorporated
product 30 with 56% yield (Scheme 40).

Scheme 39. Conjugation of 5- (β-chloro)vinyl sulfone of 2'-deoxyuridine with Lglutathione via displacement reaction
The structure of the compound 30 was determined by applying different NMR techniques
such as 1H, COSY, HMQC, DEPT-135, and

13

C. The exact mass was confirmed by taking

MALDI-TOF mass spectrometry. In proton NMR distinguished peaks of glutathione moiety
were observer at the region from 2.0- 5.0 ppm. Each peaks was figured out from their
correlation in COSY.
In carbon NMR four peaks of carbonyl carbon of the glutathione moiety were detected at
170.5, 174.0, 175.2, and 176.2 ppm. The remaining six carbon peaks of glutathione were
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observed at the region from 25.0 to 55.0 ppm. Finally, the experimental mass value of 30
verified the success of this reaction.
The success of the reaction is very encouraging because addition-elimination reaction of
nucleophile with chlorovinyl sulfone probe can be performed in physiological condition and
therefore can be explored for the bioconjugation of nucleic acid with protein. One of the
potential candidate of such protein is c-Myc protein. Note that c-Myc is a DNA transcription
regulatory protein which controls about 15% of gene expression114 and modified DNA- c-Myc
protein interaction can significantly modulate the gene expression process and thus might play
a crucial role in biological system.

Scheme 40. Substitution of halogen atoms of 5-(β-halovinyl) sulfone of uridine and 2'deoxyuridine with amino group
Interestingly, treatment of E vinyl sulfone 10 with methanolic ammonia for 3 h gave (Z)5-(1-amino-2-tosylvinyl) uridine 32 in 84% yields with a complete inversion of configuration
(Scheme 41). The plausible mechanism of the reaction can be explained as depicted in the
Scheme 42.
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Scheme 41. Plausible mechanism for the substitution of chlorine atom by amino group in
(β-halo)vinyl sulfones
If the nucleophiles after the addition-elimination type reactions are able to form
hydrogen bonding with the oxygen atom of the sulfonyl moiety, then the products possess Z
stereochemistry,89 means inversion of configuration takes place as the halo vinyl substrates
have E stereochemistry. When β-halo vinyl sulfones were treated with methanolic ammonia, it
gave the Z isomer exclusively (Figure 7).

Figure 7. Intramolecular hydrogen bonding of amino group with oxygen atom of uracil
ring and sulfone moiety
The Z stereochemistry of the vinylic position of (β-aminovinyl) sulfone analogue 32 was
confirmed by Tsui from X-ray crystallography.89 However, crystal was not obtained from the
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5 modified amino vinyl sulfone analogue 32 as it readily converted into corresponding β-keto
sulfone analogue during the approach to get crystal in MeOH or CH3CN solvent.

Figure 8. Structure of β-aminovinyl sulfone analogue 33 (left) and its X-ray structure
(right).89
The Z-5-(β-amino)vinyl sulfone of uracil derivative 35 was synthesized from the
corresponding E-5-(β-chloro)vinyl sulfone analogue 34.90 In the NOESY experiment
correlation was observed between the vinylic and H6 proton in 35. This correlation is only
possible when vinyl position possesses Z stereochemistry. It is important to mention that in
similar NOESY experiment with E-5-(β-chloro)vinyl sulfone 34 no correlation observed
between those two protons (Figure 9).

Figure 9. NOESY correlation between the vinylic proton and the H6 proton
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Interesting findings from the NOESY experiments and the recent literature report by Tsui
leads me to draw the conclusion that the vinylic position of the novel (β-amino)vinyl sulfone
analogue 32 possesses Z stereochemistry.
However, when β-halo vinyl sulfones were treated with butyl amine, the product 33 was a
mixture of E/Z isomers. The rationale for this can be explained that amino group has two
hydrogen atoms which can form two intramolecular hydrogen bondings as shown in figure 10.
The butyl amino group has only one hydrogen atom attached to the nitrogen atom which can
form hydrogen bonding either with oxygen atom of the uracil base or oxygen atom of the
sulfonyl group. This competition might results the mixtures of E/Z isomers.

Figure 10. Intramolecular hydrogen bonding in (β-aminobutyl)sulfone 33
To study the kinetics of the addition-elimination reactions of these halo vinyl sulfone and
to compare reactivity of these halovinylsulfones with the unhalogenated vinyl sulfones, the
(E)-5-(2-tosylvinyl)uridine (36) was synthesized.115 Thus treatment of 5 with p-toluenesulfinic
acid in the presence of copper(II) acetate catalyst followed by acetyl deprotection gave 36
with 35% yield (Scheme 43).

38

Scheme 42. Synthesis of (E)-5-(2-tosylvinyl)uridine
The structure of 36 was established by applying different NMR techniques and molecular
weight was determined by high resolution mass spectrometry. In 1H NMR, two vinylic proton
showed two doublet at 7.19 and 7.62 ppm respectively. The coupling constant value was 15.0
Hz which indicated that the vinylic position possessed E stereochemistry. In addition the tosyl
peak was observed at 7.39 and 7.73 ppm respectively. The experimental mass of 36 was
447.0802 [M+Na]+ which is very much similar to the theoretical value 447.0833.
3.1.3.1. Kinetics of addition-elimination reaction of (E)-5-(1-halo-2-tosylvinyl)uridine
The kinetics of the addition-elimination reactions was studied by examining reaction
profile of β-halovinylsulfones 10, 11, 12, or 36 with n-propenthiol. Kinetic data for the
reactions between β-halovinylsulfone 10, 11, 12, and 36 and n-propanethiol in the presence of
TEA were acquired by 1H NMR at room temperature using a Bruker 400 MHz spectrometer.
For each of the experiment propanethiol (200 μL of the 29.8 mM in DMSO-d6) was added to
NMR tube containing 200 μL of the 29.8 mM of β-halovinylsulfone (10, 11, 12, and 36) in
DMSO-d6 and the proper ratio of PrSH to substrates (10, 11, 12, and 36) was confirmed by
proton integration. Then TEA (200 μL of the 29.8 mM in DMSO-d6) was added for the total
9.93 mM concentration of substrates and the reaction mixture was scanned once every 5
minutes over first 30 minutes and later every 10 min. The procedure was repeated in
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duplicate. For each of the halovinyl sulfones 10, 11, 12 tested, proton spectra showed
formation of the substitution product 27. However, unsubstituted vinyl sulfone 36 was
unreactive in that nucleophilic environment. The profile for the reaction was measured by
integrating disappearance of the signal of H6 of substrate 10, 11 , and 12 at 8.25, 8.21, and
8.07 ppm and appearance of H6 signal at 7.96 ppm for the product 27 on 1H NMR spectra.
The y-intercept for each plot was set up to 1/[starting β-halovinylsulfone concentration]. Plots
show data collected within ~40% (10), ~55% (11) and ~60% (12) conversion to the β(propylthio)vinylsulfone (27) product.
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Figure 11. The rate plots for the reactions between 10 (chloro), 11 (bromo), and 12 (iodo)
with n-propanethiol in the presence of TEA. The second order rate constant was calculating
by plotting 1/[β-halo vinyl sulfone] as a function of time
The calculated second order rate constants for the substitution reaction were 0.0096 M-1s-1,
0.0192 M-1s-1 and 0.0228 M-1s-1 for 10 (chloro), 11 (bromo), and 12 (iodo), respectively. Plots
depicted in Figure 11 showed that iodo and bromo vinylsufones are more reactive compare to
chloro counterpart (I ≥ Br > Cl).
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3.1.3.2. Mechanism and stereochemistry
When β-substituted vinylsulfones were dissolved in protic polar deuterated solvent the
alpha vinylic proton exhibited interesting behavior. Thus, when β-amino vinyl sulfone 32 was
dissolved in D2O or MeOH-d4 the alpha-vinylic proton underwent quick exchange with
deuteriumto give deuterium labeled compound 37 (Scheme 44).

Scheme 43. Deuterium exchange at vinylic proton of 5- (β-aminovinyl) sulfone of uridine
to afford α-deuterated analogue
When 10 was dissolved in MeOH-d4, no deuteration at the vinyl proton was observed.
However in the presence of triethyl amine deuteration of the vinylic proton was observed and
gave deuterated compound 38 (Scheme 45). However, the rate of deuteration of chlorovinyl
analogue 10 was slow compare to the amino analogue 32.

Scheme 44. Deuterium exchange at the vinylic proton of β-chloro analogue
In the presence of propanethiol and triethyl amine fast deutaration was observed and
afforded the α-deuterated compound 39 as shown in Scheme 46.
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Scheme 45. Deuterium exchange at vinylic proton of β-chloro sulfone to give α-deuterated
β-propanethio-analogue
From these observations the plausible mechanism of the addition-elimination reaction
could be proposed (Scheme 47). The β-carbon of the vinyl sulfone is vulnerable to the
nucleophilic attack as it is partially positive due to the inductive effect of the halogen atom
and neighboring electron withdrawing sulfonyl moiety. So, subsequent attack of the
nucleophile and elimination of halogen atom give compound 43. It is also observed that under
nucleophilic condition (PrSH/MeOH-d4/TEA) the vinylic proton is exchanged by deuterium
to give compound 44. It is entirely possible that enolate like basicity of intermediate 41 is
quenched by deuterium and subsequent deprotonation of more acidic proton of intermediate
42 gave deuterium incorporated compound 44.
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Scheme 46. Plausible mechanism for substitution of halogen in β-halovinyl sulfones with
nucleophiles
Deuterium exchange was observed when β-amino vinyl sulfone 31 is treated with DMSOd6/D2O or MeOH-d4. However, vinyl thiether analogue 27 did not undergo such exchange in
MeOH-d4 in the presence of TEA. Although deuterium exchange of the vinyl proton was
observed in the chlorovinyl sulfone analogue 10 in MeOH-d4 in the presence of TEA, this
exchange was slower compare to the aminovinyl analogue 31. In addition, in the presence of
nucleophilic condition (PrSH/ TEA/ MeOH-d4) deuterium exchange occured faster compare
to the absence of propane thiol. From this behavior of chlorovinyl compound 10, it is believed
that faster deuterium acquision occurs through intermediate 42 instead of intermediate 45.
It is reported in the literature3-4 that the expected β-halo vinyl sulfone should have
possessed E configuration at the double bond. In order to establish unequivocally the
stereaochemistry

in

the

novel

nucleoside

analogues,

crystal

of

5-(1-chloro-2-

tosylvinyl)uridine (10) was obtained by slow evaporation of ACN in H2O. X-ray analysis of
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the single crystal of 10 was accuired in Dr. Raptis’s Lab at FIU from the X-ray analysis E
stereochemistry around double bond was concretely established (Figure 12).90

Figure 12. Ball-and-stick representation of 5-(1-chloro-2-tosylvinyl)uridine 10 showing
the atom labeling scheme. H-atoms and interstitial H2O molecules are omitted for clarity.
In 5-(1-chloro-2-tosylvinyl)uridine 5 the glycosyl torsion angle C6−N1−C1′−O4′ is 43.9°,
and the furanose pseudorotation angle is 164.9° (2T3 conformation). The C3′−C4′−C5′−O5′
torsion angle is 53.6° and is in the g+/gg range. Nearly parallel uracil and benzene ring
orientation allowed favorable π-π interactions.
After addition-elimination reaction, the stereochemistry of the vinyl position of the
products was studied. The crystal of the model compound 1-N-Benzyl-5-(1-(propylthio)-2tosylvinyl)uracil 45 was developed by the slow evaporation of acetonitrile and
stereochemistry was confirmed after running X-ray of the crystal.
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Figure 13. Ball-and-stick representation of 1-N-benzyl-5-(1-propanethiovinyl)uracil 45
showing the atom labeling scheme. Disordered parts and H-atoms are not shown for clarity
The 1-N-benzyl-5-(1-propanethiovinyl)uracil 45 crystallizes in the monoclinic P21/n space
group with the whole molecule in the asymmetric unit. The molecule contains four
intermolecular H-bonds including two from the uracil base: (N1-C13: 2.867(9) Å and N3-O5:
2.920(4) Å). Compare to corresponding β-ketosulfone analogue as discussed in (Section
3.2.1), the pi-pi interactions are weaker.
From the X-ray data it is clear that the propanethio analogue 45 possesses E
stereochemistry. That means after the addition-elimination reaction the E configuration of the
double bond remained unchanged for that substituted product. As an amino group can form
hydrogen bonding with oxygen atom of the tosyl group and the uracil moiety, it was
interesting to explore the stereochemistry of the double bond of the nucleoside analogue 5-(1amino-2-tosylvinyl) uridine 32. As crystal of amino compound was not obtained, the
stereochemistry of the double bond having amino group was determined by analyzing the 1N-benzyl-5-(1-amino-2-tosylvinyl)uracil (35) by NOESY techiques. In a NOESY experiment,
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the vinyl proton of chloro compound did not show any correlation with H6 proton while in the
amino compound the vinyl proton showed strong correlation with the corresponding H6
proton (Figure 9). This correlation could be only possible if the double bond of the vinilic
position possesses Z stereochemistry. So, the amino analogue 31 has Z stereochemistry at the
double bond due to the formation of hydrogen bonding of the amino group with the sulfonyl
moiety of the tosyl group. The Z stereochemistry at the double bond of analogue 31 is totally
consistent with the literature report published by Tsui et al.89
3.2. Chemistry of 5-(2-tosylacetyl)uracil and cytosine nucleosides
The C-5 position of the pyrimidine nucleoside is an active site where different reactive
functional groups such as alkene, alkyne, azide etc can be incorporated to synthesize novel
pyrimidine nucleosides.116 So, acetylene functional group was incorporated at the C-5 position
of the pyrimidine nucleosides. The 5-(1-chloro-2-tosylvinyl)pyrimidine nucleosides were
synthesized via halovinyl sulfonylation reactions as discussed above in section 3.1.1. These
(β-chloro)vinyl sulfones 46 were converted into the corresponding β-keto sulfones 47 by the
treatment of 46 with methanolic ammonia followed by acid hydrolysis of the intermediary (βamino)vinyl sulfone (Scheme 48).

Scheme 47. Synthesis of β-keto sulfone from β-chloro vinyl sulfone analogue via
substitution by ammonia and acid hydrolysis
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The plausible mechanism for the conversion of 46 to 47 can be explained in the following
way. Firstly, conversion of (β-chloro)vinyl sulfone (e.g. 46) into (β-amino)vinyl sulfone
occurs via addition-elimination reactions as depicted in Scheme 42. The basic amino group in
(β-amino)vinyl sulfone I accepts proton in acidic media and developed positive charge at the
nitrogen atom to give intermediates II (Scheme 49). Water attacks at the β-carbon of II follow
by elimination of ammonia pathway afford intermediate IV. Subsequent deprotonation and
tautomerization generates β-keto sulfone VI.

Scheme 48. Plausible mechanism of the conversion of β-amino sulfone into β-keto sulfone

Since the α-proton of β-keto sulfone is acidic (pKa = ~9-10) and under sufficient basic
conditions the α-carbon can trap electrophile. From this assumption, different electrophiles
can be inserted at the α-carbon of the β-keto sulfone analogues as illustrates in Scheme 50.
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Scheme 49. General scheme for the trapping of eletrophiles at the α-carbon of β-keto
sulfone
The plausible mechanism of this reaction is very straightforward and is depicted in
Scheme 51. First the base picks up an acidic proton from the α-carbon and thus generates
carbanion II which can be stabilized by forming enolate ion III. The π electron of the enolate
ion attacks the electrophile and gives product IV as mixture of isomers. The rationale of
forming products IV can be explained from the sp2 hybridization of α-carbon of III which can
attack electrophile either from the top face or bottom face.

Scheme 50. Plausible mechanism of electrophile trapping at the α- carbon
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3.2.1. Synthesis of 5-(2-tosylacetyl)uracil nucleosides
Initially the synthesis of uracil 5-(β-keto)sulfone were attempeted by pyridine-catalyzed
oxidative radical reaction of 5-ethynyluracil analogues. Thus, treatment of 1-N-benzyl-5ethynyluracil 48 with p-toluenesulfinic acid and pyridine in the presence of oxygen afforded
5-(β-keto)sulfone derivative 49 with the yield of 44% (Scheme 52).

Scheme 51. Synthesis of 5-(β-keto)sufone of 1-N-benzyl-5-ethynyluracil
The 5-(β-keto)sulfone 49 was characterized by NMR techniques and mass was confirmed
from HRMS-TOF analysis. In 1H NMR the α-methylene peak was observed at 4.98 ppm and
three peaks from tosyl group appeared at 2.42, 7.29 and 7.79 ppm. In 13C NMR the methylene
carbon peak appeared at 52.9 ppm while β-carbonyl carbon peak was detected at 183.8 ppm.
Treatment of acetyl protected 5-ethynyl-2'-deoxyuridine 4 with p-toluenesulfinic acid by
pyridine-catalyzed aerobic oxidative reaction afforded protected 5-(β-keto)sulfone analogue
50a with 16% yield (Scheme 53). Analogous treatment of protected 5-ethynyluridine 5 with
sulfinic acid afforded 50b with 20% yield. The low yield of these reactions could be explained
by the acid sensitive β-glycosidic bond which cleaved during the reaction. Both of the
products were characterized using NMR techniques.
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Scheme 52. Synthesis of 5-(β-keto)sufone of protected uridine from the corresponding 5ethynyl substrates
In 50a the two peaks of α-methylene proton were observed at 4.95 and 5.05 ppm and the
three tosyl peaks appeared at 2.45, 7.35, and 7.85 ppm. In 50b the two peaks from αmethylene protons appeared at 4.90 and 5.10 ppm. The chemical shift value of H6 for both
50a and 50b were appeared in the relatively downfield region compared to the 5ethynylsubstrates 4 and 5 (8.50 ppm vs 7.83 ppm) probably the result of the incorporation of
electron withdrawing β-keto sulfonyl moiety at the C5 position.
As a result of the low yield of the oxidative radical process, the 5-(β-keto)sulone of uracil
nucleosides were synthesized from their 5-(β-halo)vinylsulofne precursors by applying one
pot synthetic protocol as depicted in Scheme 48. Thus, acetyl protected (8) or unprotected (910) β-chlorovinyl sulfone analogues of uracil nucleosides were efficiently converted into
corresponding β-keto sulfones (51-52) by a one pot synthetic protocol. Thus, treatment of the
vinyl sulfones (8-10) with methanolic ammonia gave β-amino vinyl sulfones in quantitative
yield. Subsequent acid hydrolysis of these β-amino vinyl sulfones in acetonitrile gave β-keto
sulfones in high yield. Analogoulsy, acetyl protected β-chlorovinyl sulfones 8 was converted
into corresponding β-keto sulfone with 60% (52) yields and unprotected chlorovinyl sulfone
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analogues 9 and 10 into corresponding β-keto sulfones afforded 74% and 70% yields
respectively (Scheme 54).

Scheme 53. Synthesis of 5-(β-keto)sulfone of uridine and 2'-deoxyuridine from their (βchlorovinyl) sulfone analogue
The structure of (β-keto) sulfone analogues 51 and 52 were established using different
NMR (1H, COSY, HMQC, DEPT-135 and
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C) techniques. In 51 and 52, a higher chemical

shift value of H6 proton was observed at 8.68 and 8.80 ppm respectively as compared to the
chemical shift value of H6 proton in the corresponding β-chlorovinyl sulfone substrates 8-10.
The reason of higher chemical shift value of the keto analogues can be explained by the
incorporation of electron withdrawing keto group at C5 position. In compounds 51 and 52, the
peaks of methylene group appeared at 5.15 and 5.14 ppm respectively. In β-keto sulfone
analogues 51 and 52, characteristics peaks of carbonyl carbon were observed at 184.0 and
185.0 ppm respectively. In addition, distinct peak of methylene carbon peaks were observed at
64.0 and 64.3 ppm respectively. In agreement with the proton NMR there was also higher
chemical shifts value of C6 carbon peaks those were 149.0 and 149.3 ppm respectively. The
mass obtained from the high resolution mass spectroscopy (HRMS) was in accord with the
calculated value.
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The single crystal of 1-N-benzyl-5-(2-tosylacetyl)uracil (49) for X-crystallography was
obtained by diffusion crystallization (ethyl ether into a MeOH solution) of the corresponding
aminovinylsulfone 35. Compound 49 was crystallized in the triclinic P-1 space group with the
whole molecule in the asymmetric unit. Several intermolecular H-bonds stabilize the crystal
structure, including a uracil N-O H-bond (N3-O4: 2.900(3) Å) (Figure 14). The (β-keto)
sulfone analogue 49 is also stabilized by an intermolecular C-H-π-interaction between the
tosyl methyl group and the phenyl ring from the benzyl group (C(H)-centroid distance: 3.893
Å). The π-π interaction usually present between the uracil and the tosyl groups is weak or
negligible in this analogue possibly due to other H-bonding and C-H-π interactions mentioned
above.

Figure 14. Ball-and-stick representation of 1-N-benzyl-5-(2-tosylacetyl)uracil (49); Hatoms have been hidden for clarity
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3.2.1.1. Electrophile trapping at the α- carbon of the corresponding β-keto sulfone
Since the α-CH2 proton in β-keto sulfones is acidic (pKa = 10-11) the β-keto sulfone
analogues (51-52) when treated with different electrophile sources such as benzyl bromide,
methyl iodide, allyl bromide in the presence of dilute NaOH can serve as a convenient
substrates for the synthesis of α-alkylated products 53-56 (Scheme 55).

Scheme 54. Incorporation of electrophiles at the α-carbon of (β-keto) sulfone of uridine
and 2'-deoxyuridine
It is interesting to see that during the electrophile trapping, diastereomeric products were
obtained and the ratio of the diastereomers varied upon treatment with different electrophiles.
When benzyl bromide was used as electrophile source 51 gave (50/50) mixtures of
diasteremeric product 53 with 28% yield. The reason of getting low yield was the formation
of byproducts. Apart from the expected diastereomeric products, there were two additional
compounds were characterized. First byproduct was benzylated product at N3 position and the
second one was a consequence of benzylation both at N3 and α-carbon of the β-keto sulfone.
Surprisingly, dibenzylation at α-carbon was not observed. In 53 two peaks of H6 proton at 8.6
and 8.7 ppm with the integration ratio of 1:1 were observed which can be considered as the
evidence for a 50/50 diastereomeric product. In 1H NMR triplet at 6.5 ppm was observed
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which indicated the C proton. The methylene proton of the benzyl group was detected at 3.13.2 ppm as a multiplet. In addition the aromatic peak of the benzyl group was observed in the
region from 7.0-7.3 ppm. In 13C NMR the α-carbon peak was observed at 55.0 ppm while the
methyl carbon peak of benzyl group was detected at 31.0 ppm. The aromatic peaks of the
benzyl group were found in the region from 126.0-131.0 ppm which collapsed with the tosyl
peaks. The mass obtained from the high resolution mass spectroscopy (HRMS) of compound
53 was 515.1437 [M+H]+ which is in accord with the calculated value.
Treatment of 51 with methyl iodide afforded (48/52) mixtures of diasteriomeric product
54 with the yields of 31%. In addition, two other byproducts were also observed. These
byproducts were characterized as N3 methylated byproduct and both N3 and α-carbon
methylated byproduct. Like benzylation reaction, dimethylated product at α-carbon was not
observed. In this α-methylated analogue 54 two proton peaks of H6 at 8.71 and 8.73 were
observed with the integral ratio 96: 104 which meant that the diasteriomeric ratio was 48/52.
The α-CH proton peak was observed at 5.96 ppm as a quartet while the methyl peak was
observed at 1.34 ppm. In 13C NMR α-C peak was observed at 66.0 ppm and the methyl carbon
peak was found at 10.0 ppm.
Analogous treatment of 51 with allyl bromide gave 55/45 mixtures of diastereomeric
product 55 afforded 31% yield. In addition, two byproducts were also produced in similar way
as discussed before. The 104: 96 integral ratio of H6 proton of the α-substituted analogue 55
at 8.70 ppm and 8.75 ppm indicated the diastereomeric ratio is 52:48. The α-CH peak was
detected as a doublet at 6.15 ppm. The allyl sp3 hybridized CH2 proton peak was obtained at
2.8 ppm and sp2 hybridized CH proton peak was detected at 5.6 ppm. The sp2 hybridized CH2
proton peak of allyl group was observed at 5.0 ppm. In 13C NMR α-carbon peak was observed
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at 68.0 ppm. The three carbon peaks of allyl group were found at 30.0, 118.0 and 133.0 ppm
respectively.
Treatment of 52 with allyl bromide afforded allyl substituted product 56 with the as a
diastereomeric mixtures of 52/48 with the yields of 32%. Two byproducts were obtained in
the similar way as discussed before. No disubstitution observed at the α-carbon. In 56 the
integral ratio of H6 proton indicated the diastereomeric product was a 52/48 mixtures. The
multiplet at 6.14-6.20 ppm confirmed the presence of α-CH peak. The three vinyl peaks was
observed at 2.8, 4.9 and 5.6 ppm respectively. In
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C NMR α-carbon peak was observed at

69.0 ppm. The allyl peaks were observed at 30.0, 127.0 and 133.0 ppm respectively.
The 5-(α-iodo-β-keto)sulfone of 2'-deoxyuridine 56 was synthesized as an alternative
probe to incorporate nucleophile at the α-carbon of the corresponding sulfones via substitution
reaction. Thus, treatment of β-keto sulfone analogue 51 with iodine monochloride afforded 5(α-iodo-β-keto) sulfone of 2'-deoxyuridine 56 as 50/50 mixtures of diastereomeric mixtures
with the yields of 44% yield (Scheme 56). Alternatively 56 was also synthesized using
molecular iodine in the presence of hydrogen peroxide and acetic acid and the yield was 55%.

Scheme 55. Synthesis of 5-(α-iodo β-keto sulfone) of 2'-deoxyuridine

The structuce of the novel probe 56 was established by using different NMR techniques.
In 1H NMR α-proton of CH group was observed at 7.30 ppm. The higher chemical shift value
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of this proton can be explained as the incorporation of the relatively electronegative iodine
atom at the α-carbon. In 13C NMR the α-carbon peak was observed at 128.0 ppm
3.2.1.2. Nucleophile trapping at the α-carbon of the β-keto sulfones
Treatment of 5-(α-iodo-β-keto) sulfone 56 with propane thiol in the presence of
triethylamine gave propane thio nucleophile incorporated product 60 as a 50/50 mixture of
diasteromers and yield was 20% (Scheme 57). Relatively low yield of this reaction could be
explained due to the formation of methyl ester as by product which was the major product in
this reaction.

Scheme 56. Synthesis of 5- (α-propanethio β-keto sulfone) of 2'-deoxyuridine
The structure of the compound 57 was established by NMR techniques. Thus, in 1H NMR
three signals of the propanethio group were observed at 2.80-2.85 (multiplet), 1.40-1.60
(multiplet), and 0.85 (triplet) respectively. This ractions implied the feasibility of the
incorporation the thiol residue of the important amino acid cysteine at the α-position of the
corresponding β-keto sulfone analogue 56.
3.2.2. Synthesis and reactivity of 5-(2-tosylacetyl)cytosine nucleosides
Acetyl protected β-chlorovinyl sulfone analogues (19-20) of cytosine nucleosides have
been efficiently converted into corresponding β-keto sulfones (58-59). Thus treatment of the
(β-chloro)vinyl sulfones (19-20) with methanolic ammonia gave β-amino vinyl sulfones in
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excellent yield. Subsequent acid hydrolysis of these β-amino vinyl sulfones in acetonitrile
gave β-keto sulfones (61-62) in good yield (Scheme 58)

Scheme 57. Synthesis of 5-(β-keto)sulfone of cytidine and 2'-deoxycytidine
When β-chlorovinyl sulfones were treated with methanolic ammonia, it converted into the
corresponding β-aminovinyl sulfones with the deprotection of the acetyl group
simultaneously. When β-chlorovinyl sulfones 19 and 20 were converted into corresponding βketo sulfone the yields were 68% (58) and 57% (59) respectively.
The structures of these β-keto sulfone analogues (58-59) were determined by applying
different NMR techniques and actual mass was obtained from high resolution mass
spectrometry. In β-keto sulfone analogues 58 and 59, chemical shift value of H6 proton was
observed at 9.0 and 9.05 ppm respectively which was higher compare to chemical shift value
of H6 proton of the corresponding β-chlorovinyl sulfone analogues 19 and 20. The higher
chemical shift value of the keto analogues can be explained by the incorporation of electron
withdrawing keto group at C5 position. In 58 methylene peak was appeared at 4.80-5.0 ppm
as doublet of doublet. In 59, the same peak was observed at 4.75-4.98 ppm as doublet of
doublet. In 58 and 59, characteristics peaks of β-keto carbonyl carbon were observed at 185.0
and 186.0 ppm respectively. In addition characteristic peaks of methylene carbon of these
compounds were also observed at 62.4 and 63.0 ppm respectively. In complete accord with
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the proton NMR, the higher chemical shift value of C6 carbon was observed at 152.0 and
152.5 ppm respectively. The mass obtained from the high resolution mass spectroscopy
(HRMS) of compound 58 was 446.1002 [M+Na]+. The theoretical mass of the compound was
also 446.1002 [M+Na]+ means the theoretical mass was in complete accord with the
experimental value of the corresponding compound
The β-keto sulfone analogues of cytosine nucleosides (58-59) were treated with different
electrophiles and these electrophiles were efficiently trapped at the α-carbon of the
corresponding keto sulfone analogues with high yield. Thus treatment of β-keto sulfone
analogue 58 with benzyl bromide in the presence of dil. NaOH, the α-benzylated product 60
was obtained as a 52/48 mixture of diastereomers with 68% yield. Interestingly, no
dibenzylation at the α-carbon was observed (Scheme 59).

Scheme 58. Synthesis of 5-(α-subsitituted β-keto sulfone) of cytidine and 2-deoxycytidine
The structure of the benzylated product 60 was established by applying different NMR
techniques. In 1H NMR two multiplets of α-proton was observed at 5.45-5.52 and 5.55-5.62
ppm. In addition methylene proton of benzyl group was found at 3.30-3.40 ppm as a multiplet.
Aromatic proton of benzyl group was observed at 7.05-7.25 ppm. In 13C NMR α-carbon peak
was obtained at 69.0 ppm. The methylene carbon peak of benzyl group was observed at 32.0
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ppm and the aromatic peaks were collapsed with the tosyl peaks in the region between 127.0
ppm to 130.0 ppm.
Analogues treatment of 59 with benzyl bromide in the presence of dil. NaOH afforded αbenzylated product 61 with 67% yield (Scheme 59). Benzyl disubtitution at α-carbon was not
observed. In 1H NMR of 61, α-proton peak was appeared at 5.60-5.70 ppm as a multiplet. The
methylene peak of benzyl group was observed at 3.18-3.30 ppm as a multiplet. The aromatic
peaks were appeared at7.10-7.25 ppm. In

C NMR the α-carbon peak was appeared at 70.0
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ppm. The methlene carbon peak of benzyl group was found at 31.0 ppm. Aromatic peak of the
benzyl group was observed at the region from 126.0 to 129.0 ppm which collapsed with the
tosyl peaks.
Treatment of compound 58 with methyl iodine in basic medium gave 52/48 mixture of
diastereomers 62 with 68% yield (Scheme 59). As usual no dimethylation observed at the αcarbon. Analogue 62 was characterized by applying different NMR techniques. In 1H NMR αproton peak was observed at 5.20-5.30 ppm. The methyl proton was appeared at 1.32-1.38
ppm. In 13C NMR peaks of α-carbon and methyl group were found at 64.0 ppm and 12.0 ppm
respectively.
3.3. Incorporation of (β-halo)vinyl sulfone probes at 8-position of 2'-deoxyadenosine
The β-halo sulfonylation reaction was also extended into the purine nucleosides by the
reaction of terminal alkyne group via halosulfonylation reactions. Thus the acetylene group
was incorporated at the 8 position of the 2'-deoxyadenosine analogue following the literature
procedure117,118 which involved TBDS protection at the sugar moiety, bromination at 8
position, Sonogashira coupling, and silyl deprotection as depicted in Scheme 60.
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Scheme 59. Synthesis of protected 8-acetylene 2'-deoxyadenosine

Scheme 60. Attempted halosulfonylation of 8-ethynyl -2'-deoxyadenine 23 with tosyl
hydrazide. Synthesis of 8-(1-chloro-2-tosylvinyl)adenine
Treatment of 2'-deoxy-3',5'-bis(O-tert-butyldimethylsilyl)-8-ethynyl adenosine 66 with
tosyl hydrazide gave 8-(1-chloro-2-tosylvinyl)adenine (67) with the yields of 44% (Scheme
61). In this halosulfonylation reaction the cleavage of β-glycosidic took place which was
confirmed from the proton NMR as there was no peak of the sugar moiety observed. In aditio
there was a peak of the NH proton observed at 13.5 ppm. The vinyl peak was observed at 7.90
ppm. The three tosyl peaks were appeared at 2.40, 7.45, and 7.80 ppm. In the carbon NMR of
67, vinyl peak was detected at 136.4 ppm while the C-Cl peaks appeared at 143.0 ppm. The
five tosyl peaks were found at 21.0, 128.0, 130.0, 135.0, and 145.0 ppm.
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Scheme 61. Synthesis of 8-(β-iodovinyl)sulfone analogue of 2'-deoxyadenosine
Interestingly when silyl protected 8-ethynyl adenosine analogue 66 is reacted with sodium
salt of p-toluenesulfinic acid and iodine, no glycosidic bond cleavage was observed. Thus,
treatment of 66 with sodium tosylate and iodine in the presence of sodium acetate afforded 8(β-iodovinyl)sulfone of silyl protected 2'-deoxyadenosine analogue 68 with 48% yield
(Scheme 62). In the proton NMR of 68 the vinyl peak was observed at 7.60 ppm. The three
tosyl peaks were appeared at 2.40, 7.25, and 7.70 ppm. In the carbon NMR of the vinyl peak
was detected at 136.0 ppm while the C-I peaks appeared at 129.0 ppm. The C_H peaks from
tosyl group were converged at 130.0 ppm. The successful conversion of 8-ethylnyl-2'deoxyadenosine 66 to 8-(β-iodovinyl)sulfone of 2'-deoxyadenosine 68 showed that
halovinylsulfonylation can be extended to the purine nucleoside analogues.
3.4. Incorporation of (E)-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine nucleotide at DNA
3.4.1. Synthesis of 5'-phosphates
Phosphorylation is an important technique to study important biological properties of the
nucleotides in living cell. Phosphorylation at 5' position of the 2'-deoxynecloside analogues
are widely useful technique to DNA polymerase mediated incorporation in DNA. Here novel
5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine analogues have been triphosphorylated at 5'position in order to polymerase mediated incorporation in DNA and to study the DNA-protein
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interaction by reacting with protein molecules. Phosphorylation was accomplished by
applying modified Yoshikawa method.119

Scheme 62. Synthesis of 5'-monophosphate of 5-(β-chlorovinyl sulfone) of 2'deoxyuridine by modified Yoshikawa method
Treatment of β-chlorovinyl sulfone analogue 9 with 1.8 equiv. of phosphoryl chloride in
the presence of 2.0 equiv. of proton sponge in trimethyl phosphate solvent at 0 oC gave 5dichlorophosphate intermediate 70 in very good yield (~70%; TLC). Subsequent treatment of
intermediate 70 with 4.2 equiv. of tributylammonium pyrophosphate (TBAPP) and 2.7 equiv.
of tributylamine (TBA) at rt afforded 5'-triphosphorylated analogue 71 in moderate yield
(32%) as depicted in Scheme 64. Alternatively, the intermediate 70 have been efficiently
converted into 5'-monophosphate 69 by quenching the reaction with TEAB buffer.
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Scheme 63. Synthesis of 5'-triphosphate of 5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine

The 5'-triphosphosphate 71 was characterized by applying different NMR techniques such
as

31

P, 1H, COSY, HMQC, DEPT-135,

13

C; and FT-ICR mass spectrometry. In phosphorous

NMR three peaks were observed at δ -23 (β-P), -11.5 (α-P), -10.5 (γ-P). The peaks at -23.0
ppm confirmed that triphophorylation had been taken place as β-phosphorous atom of
triphosphorylated compound gave peak at around -23.0 ppm. The chlorine atom of βchlorovnyl sulfone analogue was readily substituted by nucleophile through additionelimination type reaction. So, it was a concern whether the chlrorine survived at that basic
condition after triphosphorylation reaction. However, the mass spectrum showed the presence
of chloride as it has a classic isotopic pattern at the molecular ion peak and the peak intensity
is 3:1. The observed molecular mass was 680.95172 [M-H]- which was in very good
agreement with the theoretical mass of the compound 680.95186 ppm and the mass error was
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only 0.2 ppm. All the proton and carbon peaks were assigned by analyzing different NMR
spectrum and all the values were in accordance with the expected values.
3.4.2. DNA polymerase catalyzed incorporation into DNA
To study the bioconjugation of the novel (β-chloro)vinyl sulfone analogue with proteins in
vivo, it is indispensable to incorporate this novel probe into DNA. The phosphorylated (βchloro)vinyl sulfone analogue 71 was incorporated into double strand DNA by using DNA
polymerase where the extent of incorporation was tested both in DNA leading and lagging
strand by using bacterial replication DNA polymerase, the Klenow fragment of DNA
polymerase I (pol I) and human repair DNA polymerase, DNA polymerase  (pol ). The
concentration of the DNA pol I (pol I) was 5 U in each time, however different concentrations
of DNA polymerase  (pol ) such as 0.5 nM, 1 nM, 5 nM, 10 nM, 25 nM, and 50 nM were
used. The concentration of the (β-chloro)vinyl sulfone analogue 71 was 50 μM. The
polymerase mediated DNA incorporation was monitored by applying polyacrylamide gel
electrophoresis (PAGE) technique. The details of nucleotide sequence and number, primer,
and template are tabulated below:
Table 3. Detailed information of nucleotides used during polymerase mediated
incorporation
Nucleotide
Upstream primer
# Downstream primer

Template

nt

Sequence (5'-3')

31

GCA GTC CTC TAG TCG TAG TAG CAG
ATC ATC A

39

CAA CCG GCA TTA GGT GTA GTA GCT
AGA CTT ACT CAT TGC

71

GCA ATG AGT AAG TCT AGC TAC TAC
ACC TAA TGC CGG TTG ATG ATG ATC
TGC TAC TAC GAC TAG AGG ACT GC

# Downstream primer was used only in one nucleotide gap DNA template
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Figure 15. Incorporation of (β-chloro)vinyl sulfone analogue into DNA open template by
DNA polymerase
During the polymerase mediated incorporation approach of the substrate 71 in DNA open
template which leads to DNA synthesis, human repair DNA polymerase (pol ) was unable to
incorporate the substrate into DNA at any of the concentration mention above (Fig.15, Lane
8-12). However, bacterial polymerase pol I can efficiently incorporated the substate (Figure
15, Lane 13) at 5 U concentrations like the natural substrate deoxythymidine triphosphate
(dTTP). However due to the excessive activities of the pol I on the substrate one more unit of
the substrate 71 incorporated and thus mismatch happened which was obvious in PAGE
analysis (Figure 15, Lane13).
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Figure 16. Incorporation of (β-chloro)vinyl sulfone analogue into DNA one gap
nucleotide template by DNA polymerase
During the polymerase mediated incorporation of the substrate into the one gap nucleotide
template of DNA which causes lagging during the DNA synthesis, both human repair DNA
polymerase (pol ) and bacterial polymerase (pol I) efficiently incorporated the chlorovinyl
substrate 71 (Figure 16, Lane 13-15). However, human repair DNA polymerase (pol )
mediated incorporation of the substrate is dependent on the concentration of the polymerase.
From the PAGE analysis it was obvious that 0.1 and 0.5 nM concentration of pol  couldn’t
incorporate the substrate 58 (Figure 16, Lane 8-9). However, at 1.0 nm concentration of pol 
the incorporation was observed (Figure 16, Lane 10), though the extent of incorporation was
low at that concentration. With the increase of the concentration of the pol  the extent of
incorporation enhanced significantly. When 25.0 nM pol  was used the polymerase
incorporated the substrate 71 (Lane 13) as like the natural substrate dTTP (Lane 6). Similar to
the open template, 5 U concentration of pol I efficiently incorporated the substrated at the
template with the mismatched (one more unit incorporated) (Figure 16, Lane 15).
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3.4.3. Conjugation of phosphorylated chlorovinyl sulfone analogue with L-glutathione
Treatment of monophosphorylated (β-chloro)vinyl sulfone 69 with L-glutathione in the
presence of triethyl amine in methanol-water mixed solvent system gave the bioconjugated
product 72 with 55% yield (Scheme 65).

Scheme 64. Conjugation of 5-(β-chlorovinyl sulfone) of 2'-deoxyuridine-5'monophosphate with L-glutathione
The structure of the bioconjugated analogue 72 was determined by applying different
NMR techniques and experimental mass value was obtained from FT-ICR mass spectrometry
where the ionization was carried out in the negative mood.
In the proton NMR distinct peaks of glutathione were observed in the region from 2.0 to
5.0 ppm. The three amino acids peak of glutathione which are cysteine, glutamic acid and
glycine were appeared in that region. It was difficult to figure out the multiplicity of some of
the proton peaks due to the peak overlapping with the sugar moieties of the nucleosides. In
carbon NMR the four carbonyl carbon peaks of the amide and carboxylic acid groups were
observed at 171.0, 175.0, 177.0, and 177.0 ppm. The other six carbon peaks were appeared
from 25.0 to 65.0 ppm. Finally the experimental mass value which was similar with the
theoretical value confirmed the presence of 72.
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3.5. Incorporation of 5-(2-tosylacetyl)-2'-deoxyuridine nucleotide at DNA
3.5.1. 5'- Phosphorylation
Novel 5-(2-tosylacetyl)-2'-deoxyuridine analogues have been triphosphorylated at 5'position in order to polymerase mediated incorporation in DNA and to study the DNA-protein
interaction by reacting with protein molecules. Phosphorylation was accomplished by
applying modified Yoshikawa method. Treatment of β-keto analogue 51 with 1.7 equiv. of
phosphoryl chloride in the presence of 2.0 equiv. of proton sponge in trimethyl phosphate
solvent gave 5'-dichlorophosphate intermediate compound 73 in very good yield (~70%;
TLC). Subsequent treatment of 5'-monophosphorylated intermediate 73 with 4.1 equiv. of
tributylammonium pyrophosphate (TBAPP) and 2.5 equiv. of tributyl amine (TBA) gave 5'triphosphorylated analogue 74 in moderate yield (38%) as depicted in Scheme 66.

Scheme 65. 5'-Phosphorylation of 5-(2-tosylacetyl)-2'-deoxyurindine
The 5'-triphosphate 74 was characterized by applying different NMR techniques such as
31

P, 1H, COSY, HMQC, DEPT-135,

13

C; and FT-ICR mass spectrometry. In phosphorous
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NMR three peaks were observed at -23.5, -11.7, -11.0 ppm. The peaks at -23.5 ppm
confirmed that triphophorylation had been taken place as β-phosphorous atom of
triphosphorylated compound gave peak at around -23.0 ppm. It was a concerned whether the
acidic α-methylene proton survived at that basic condition. However, the presence of proton
peak at 4.20 ppm and integration value indicated the survival of the α-methylene proton. In
addition in DEPT-135 NMR α-CH2 peak was observed at 67.0 ppm which also ensured the
presence of unaffected α-methylene group. Finally the mass of the compound was determined
by ultra high resolution mass spectroscopy in negative mood. The experimental value of the
compound 72 was 662.98595 [M-H]- compared to the theoretical value 662.98575 [M-H]with a mass error of only 0.3 ppm.
3.5.2. Incorporation into DNA by DNA polymerase
Both human DNA repair polymerase (pol ) and bacterial polymerase (pol I) efficiently
incorporated β-keto sulfone analogue 74 into DNA open template. At 5 U concentration pol I
efficiently incorporated the substrate 74 like the natural substrate dTTP. However, the human
DNA repair polymerase  mediated incorporation was dependent on the concentration of the
polymerase (Figure 17)
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Figure 17. Incorporation of 5 (β-keto)sulfone analogue into DNA open template by DNA
polymerase

Incorporation started to take place at 1.0 nM polymerase concentration and at 25.0 nM pol
 the incorporation was about 50% (Figure 17, Lane 13) which increased to about 70% at 50.0
nM concentration of the polymerase .
Polymerase mediated incorporation of the (β-keto)sulfone analogue 74 into one nucleotide
gap template was observed when either of the polymerase was used. 5 U concentration of the
bacterial polymerase (pol I) efficaciously incorporated the (β-keto)sulfone analogue 74
(Figure 18, Lane 15). In this nucleotide template enhance activities of the human repair DNA
polymerase (pol ) was observed. Even at 0.1 nM of this polymerase incorporated about 50%
of the (β-keto)sulfone analogue 72 (Figure 18, Lane 9) and only 1.0 nM pol  incorporated the
substrate 74 (Figure 18, Lane 11) like the natural substrate dTTP (Figure 18, Lane 4).
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Figure 18. Incorporation of (β-keto)sulfone analogue into DNA one nucleotide gap
template by DNA polymerase

3.6. Prodrugs of C5 modified uracil nucleosides
A number of C5-modified uracil nucleoside analogues has been synthesized in our lab90
and their anticancer and antiviral activities were tested at Rega Institute for Medical Iesearch
in Belgium. Interestingly, it has been observed that the half maximal inhibitory concentration
(IC50) of the acetyl protected chlorovinyl sulofne analogue 9a against the proliferation of
murine leukemia cells (L1210) were much lower as compared to its unprotected chlorovinyl
sulfone counterpart 9 (5.6 ± 4.7 µM vs. >200 µM). Therefore, based on these findings
liphophilic long alkyl chain was incorporated at the 5' and/or 3' position of at 5-modified
analogue 9 and a number of 5-arylated analogues via esterification reaction.
.
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Figure 19. Lipophobic (9) and lipophilic (9a) 5-modified-2' deoxynucleoside analogues

3.6.1. Synthesis of prodrug of (E)-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine
To incorporate more liphophilic long alkyl chain at the sugar moiety of the nucleoside
analogues more reactive undecanoic anhydride was prepared from undecanoic acid. Thus
treatment of undecanoic acid with thionyl chloride at ambient temperature for 5 h gave
undecanoyl chloride with quantitative yield.
Treatment of undecanoyl chloride with undecanoic acid in the presence of triethylamine
gave undecanoic anhydride with quantitative yield.

Scheme 66. Preparation of undecanoic anhydride from undecanoic acid
Further treatment of undecanoyl chloride with undecanoic acid for overnight and
evaporation of volatiles under reduced pressure gave undecanoic anhydride as white solid
with quantitative yield (Scheme 67).
Treatment of β-chloro vinyl sulfone analogue 9 with undecanoic anhydride gave mono
and diprotected products from moderate to good yield. When β-chloro vinyl sulfone analogue
9 was treated with 1.2 equiv. of undecanoic anhydride for two hours, the major product was
(E)-5'-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine
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(75)

with

45%

yield.

However, treatment of β-chloro vinyl sulfone analogue 9 with 3 equiv.of undecanoic
anhydride for 6 h gave (E)-3',5'-Di-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine
(76) as major product with 75% yield (Scheme 68). Also small quantities of 3'-O-undecanoyl
product was isolated (see Experimental Part).

Scheme 67. Synthesis of undecanoate protected 5-(1-chloro-2-tosyl)vinyl-2'-deoxyuridine
Both mono and di-protected compounds 75 and 76 were characterized by applying NMR
techniques i.e 1H, COSY, HMQC, DEPT-135, 13C and mass of the products were determined
by high resolution mass spectrometry. The proton NMR peak at 0.88, 1.24-1.39, 1.62, and
2.34 ppm and integration value of number of proton confirmed the presence of one
undecanoyl group in the sugar moiety. The higher chemical shift value of H5' proton at 4.40
ppm while almost unchanged chemical shift value of H3' proton which is at 4.17 ppm
indicated that esterification took place at 5'-OH group. In addition, the presence of 3'-OH at
3.00 ppm further justified the regioselective esterification of 9. Eleven carbon peaks at 14.2,
22.0, 25.0 29.2, 29.4, 29.5, 29.7, 29.8, 32.2, 34.4, and 174.0 ppm in compound 75 indicated
the presence of one undecanoyl group. Finally, experimental mass value of 633.2013
[M+Na]+ confirmed the presence of mono protected analogue 75.
The integration values of different proton peaks at the region from 0.84 to 2.34 ppm and
higher chemical shift values of H3' and H5' at 4.42 ppm and 5.27 ppm indicated the presence
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of diprotected compound. In addition the different carbon peaks and experimental mass value
801.3505 [M+Na]+ confirmed the diprotected compound 76.
3.6.2. Synthesis of prodrug of 5-(fur-2-yl/5-heptylfur-2-yl)-2'-deoxyuridine
The 5-(fur-2-yl)-2'-deoxyuridines 78 and 80 have been synthesized from 5-iodo substrates
2 and 77 following the literature procedure.91 Analogously, tetrabutylammonium fluoride
(TBAF)-mediated direct C-H arylation of 5-iodouracil nucleosides 2 and 77 with 2heptylfuran provided 5-(heptylfur-2-yl)-2'-deoxyuridine 79 and 81.120 Treatment of
unprotected derivatives 80 or 81 with undecanoic anhydride gave mono and diacylated
products from moderate to good yield. Thus, treatment of 5-(fur-2-yl) 80 or 5-(5-heptylfur-2yl) 81 analogues with 1.2 equiv. of undecanoic anhydride for two hours afforded 5'-Oundecanoyl-5-(fur-2-yl)-2'-deoxyuridine (82) or 5'-O-undecanoyl-5-(5-heptylfur-2-yl)-2'deoxyuridine (84) with the yield of 52% and 48% respectively. Analogues treatment of 80 or
81 with 3 equiv. of undecanoic anhydride for 6 h afforded 3',5'-di-O-undecanoyl-5-(fur-2-yl)2'-deoxyuridine (83) or 3',5'-di-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (85) as
major products with the yield of 77% and 80% respectively (Scheme 69). Also small
quantities of 3'-O-undecanoyl products were isolated (see Experimental Part)

Scheme 68. Synthesis of 5-(fur-2-yl)/5-(heptafur-2-yl)-2'-deoxyuridine by direct arylation
and their undecanoate protected analogues
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Both mono and diprotected compounds were characterized by applying NMR techniques
and mass values were determined by HRMS. Accumulating the number of proton present in
the compound 82 or 84, it was confirmed that these are monoprotected compounds. The regioselectivity of the monoesterified products were confirmed by comparing the chemical shift
value of H3' and H5' proton of the products (82 and 84) with the starting compound (63 and
64) respectively. In the mono protected analogues 82 and 84 the proton peak of H5' is at 4.25
ppm and 4.28 ppm which are significantly higher than the corresponding proton of the
unprotected compounds 80 or 81. Additionally, the H3' proton peaks were almost unchanged
(4.36 ppm and 4.33 ppm respectively) in the monoprotected products (82 and 84) compared to
the unprotected ananogues (80 and 81). This could be only possible when acyl protection
takes place at 5'OH group while 3'OH group would be unprotected. In addition each of the
compound 82 and 84 has one carbon peak at 174.0 ppm which also indicated the presence of
mono-esterified products. Finally, the experimental mass value of the products 82 and 84
which are 485.2264 [M+Na]+ and 583.3359 [M+Na]+ respectively confirmed the presence of
monoprotected products.
The higher chemical shift values of H3' and H5' proton at 5.27 ppm and 4.36 ppm
respectively suggested the presence of diprotected analogue 83. The integration value of
different proton peaks at the region from 0.82 to 2.40 ppm also agreed this claim. Similar
finding was observed in diprotected 5-(heptylfur-2-yl) analogue 85. Two different carbonyl
carbon peaks and experimental mass value of 653.3778 [M+Na]+ and 751.4873 [M+Na]+
confirmed the synthesis of diprotected 5-arylated analogues 83 and 85 respectively.
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3.6.3. Selected antiviral and anticancer activities
All of the uracil nucleoside analogues (Scheme 68 and 69) were sent to our collaborators
at Raga Institute for Medical Research in Belgium to test their antiviral and anticancer
activities. The antiproliferative activity of all of the compounds (9, 9a, and 75-76) was tested
in murine leukemia (L1210), human leukemia (CEM), and human cervical carcinoma (HeLa)
cells. Only acetyl protected (β-halo)vinyl sulfone 9a inhibited the growth of those cells in
lower μM range (Table 4). Interestingly, (β-halo)vinyl sulfone derivatives with a larger acyl
protected group 75 and 76 didn’t show improved activity. The 5-(fur-2-yl) analogues (78-85)
were also tested against those carcinogenic cells and the acetylprotected 5-heptylfur-2-yl)-2'deoxyuridine 79 inhibited the T-lympocyte cells (CEM) in the μM range. Interestingly
unprotected 5-(5-heptylfur-2-yl) analogue 81 exhibited improved activity against the same
cells. Both acetyl protected analogue 79 and unprotected analogue 81 showed moderate
activities against the proliferation of murine leukemia cells (L1210) (Table 4). Unprotected 5(fur-2-yl) analogue 80 is moderately active against human cervix carcinoma cells (HeLa)
proliferation (Table 4).
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Table 4. Inhibitory effects on the proliferation of murine leukemia cells (L1210), human Tlymphocyte cells (CEM), and human cervix carcinoma cells (HeLa).120
IC50 (μM)
Compound
L1210

CEM

HeLa

9a

5.6 ± 4.7

11± 10

23 ± 8

79

65 ± 10

36 ± 3

> 100

80

>100

> 100

32 ± 1

81

48± 6

16 ± 4

> 100

84

> 100

93 ± 4

> 100

85

> 100

78 ± 16

> 100

IC50 is 50% inhibitory concentration

The 5-(β-chlorovinyl)sulfone analogues (9, 9a and 76-77) and 5-(fur-2-yl) analogues (7885) were tested against a broad range of DNA and RNA viruses and the human
immunodeficiency virus (HIV). The (β-chloro)vinyl sulfone 9a showed an EC50 of 4 μM for
the Oka strain (VZV TK+) and marginal activity against human cytomegalovirus (HCMV)
(Table 5). The 3',5'-di-O-acetyl -5-(5-heptylfur-2-yl) (79) and 5-(5-heptylfur-2-yl) (81)
derivatives inhibited the replication of HCMV and varicella zoster virus (VZV) bearing a
wild-type thymidine kinase (TK+) with 50% effective concentrations (EC50) in the range of
10-20 μM (Table 5). 5-(Heptylfur-2-yl)-2-deoxyuridine 81 was equally active against TK+ and
TK- deficient VZV mutant virus. However, neither of the arylated analogues 79 and 81 were
able to decrease herpes simplex virus 1 (HSV-1) and 2 (HSV-2) induced cytopathic effect
(Table 5).
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Table 5. Anti-herpesvirus activity of the tested compounds in HEP (human embryonic
lung) fibroblasts
Cytotoxicity

EC50 (μM)

(μM)
Compd
MCC

HSV-1

HSV-2

(KOS)

(G)

HSV-1

HCMV

-

TK (KOS

(AD-

ACV)

169)

VZV

HCMV
(Davis)

TK

+

VZV
TK-

(Oka)

(07-1)

9a

> 100

> 100

> 100

> 100

> 20

20

4

>20

79

100

> 100

> 100

> 100

10 ± 2

12 ±4

20

>20

80

> 100

4.0 ± 0

47 ± 37

> 100

45

20

32

>100

81

100

> 100

> 100

> 100

10

20

13 ±2

12 ±5

EC50 concentration required to reduce virus-induced cytopathogenicity by 50%
MCC is the Minimum Cytoxic Concentration required to cause a microscopically detectable alteration
of normal cell morphology

In contrast, the 5-(fur-2-yl)uracil nucleoside 80 emerged among the compounds
synthesized as the most potent inhibitor the HSV-1 TK+ strain Kos with an EC50 of 4 μM.
However, this analogue (80) was less active against HCMV, HSV-2, and VZV TK+ Oka strain
strain than against HSV-1 while it lacke activity against TK- HSV-1 and VZV (Table 5). The
5-(5-heptylfur-2-yl)-2'-deoxyuridine (81) displayed antiviral activities against parainfluenza
virus (Table 6) while all others compounds were inactive.
Table 6. Activity of 5-(5-heptylfur-2-yl)-2'-deoxyuridine against parainfluenza virus
Compound
81

Cytotoxicity (μM)

EC50 (μM)

MCC

Parainfluenza-3 virus

> 100

14.8 ±8

EC50 concentration required to reduce virus-induced cytopathogenicity by 50%
MCC is the Minimum Cytoxic Concentration required to cause a microscopically detectable alteration
of normal cell morphology
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4. EXPERIMENTAL
4.1. General synthetic procedures
1

H NMR spectra at 400 MHz and 13C NMR at 100.6 MHz were recorded in CDCl3 unless

otherwise noted. All chemical shift values are reported in parts per million (ppm) and
referenced to the residual solvent peaks [CDCl3 (7.26 ppm) or DMSO-d6 (2.54 ppm)] for 1H
NMR and the CDCl3 (77.16 ppm) or DMSO-d6 (39.52 ppm) for

13

C NMR spectra, with

coupling constant (J) values reported in Hz. HRMS were obtained in TOF (ESI) mode unless
otherwise specified. TLC was performed on Merck kieselgel 60-F254, and products were
detected with 254 nm light. Merck kieselgel 60 (230-400 mesh) was used for column
chromatography. Purity, yields and ratio of the products (crude and/or purified) were
established via NMR with calibrated standards. All reagents and solvents were purchased
from commercial suppliers and used without further purification. The 5-ethynylpyrimidine
nucleosides112,113 or 8-ethynyl-2'-deoxyadenosine117 were synthesized following the literature
procedure.
4.2. Synthesis
5-(1-Chloro/bromo-2-tosylvinyl)uracl/cytosine nucleosides (9a, 8-11, and 19-20).
Procedure A. 5-Ethynyluracil/cytosine and tosyl hydrazide were dissolved in the acetonitrile
and treated with iron(III) halide in the presence of tertiary butyl hydrogen peroxide at 80 oC.
The volatiles were evaporated and the residue was column chromatographed to afford (9a, 811, and 19-20).
(E)-3',5'-Di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (9a). Treatment of 3',5'di-O-acetyl-2'-deoxy-5-ethynyluridine 4 (336 mg, 1 mmol) with p-toluenesulfonyl hydrazide
(372 mg, 2 mmol) and FeCl3·6H2O (540 mg, 2 mmol) by procedure A (column
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chromatography; hexane/EtOAc, 1:1 → 4:6) gave 9a (400 mg, 76%): 1H NMR δ 2.12 (s, 3H),
2.16 (s, 3H), 2.27-2.37 (m, 1H), 2.42 (s, 3H), 2.58 (ddd, J = 1.7, 5.5, 14.3 Hz, 1H), 4.30-4.35
(m, 2H), 4.46 (td, J = 2.3, 5.0 Hz, 1H), 5.27 (d, J = 6.4 Hz, 1H), 6.35 (dd, J = 5.5, 8.5 Hz,
1H), 6.89 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H), 8.83 (s, 1H);
C NMR δ 21.02, 21.04, 21.8, 28.8, 38.2, 64.0, 74.4, 83.1, 85.7, 109.2, 127.9, 130.2, 134.7,
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136.7, 139.9, 141.5, 145.6, 149.3, 158.9, 170.5, 170.6; HRMS calcd for C22H2335ClN2NaO9S
[M+Na]+ 549.0705, found 549.0708.
(E)-2',3',5'-Tri-O-acetyl-5-(1-chloro-2-tosylvinyl)uridine (8). Treatment of 2,3,5-tri-Oacetyl-5-ethynyluridine 5 (79 mg, 0.2 mmol) with p-toluenesulfonyl hydrazide (52.2 mg, 0.28
mmol) in the presence of FeCl3·6H2O (108 mg, 0.4 mmol) by procedure A gave 8 (80 mg,
68%): 1H NMR δ 2.12 (s, 3H), 2.14 (s, 3H), 2.18 (s, 3H), 2.42 (s, 3H), 4.37-4.47 (m, 3H),
5.36-5.41 (m, 1H), 5.44 (t, J = 5.5 Hz, 1H), 6.10 (d, J = 5.3 Hz, 1H), 6.94 (s, 1H), 7.32 (d, J =
8.1 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.82 (s, 1H), 8.63 (s, 1H); 13C NMR δ 20.6, 20.7, 21.0,
21.8, 63.2, 70.4, 73.4, 80.7, 88.0, 109.4, 128.1, 130.2, 135.3, 136.7, 139.6, 141.6, 145.5,
149.2, 159.6, 169.6, 169.7, 170.5; HRMS calcd for C24H2535ClN2NaO11S [M+Na]+ 607.0760,
found 607.0755.
(E)-5-(1-Chloro-2-tosylvinyl)-2'-deoxyuridine

(9).

Treatment

of

5-ethynyl-2'-

deoxyuridine 6 (50.5 mg, 0.2 mmol) with p-toluenesulfonyl hydrazide (52.2 mg, 0.28 mmol)
in the presence of FeCl3·6H2O (108 mg, 0.4 mmol) by procedure A (column chromatography;
CHCl3/MeOH; 9:1→85:15) gave 9 (82 mg, 90%) as white solid. 1H NMR (MeOD-d4) δ 2.252.34 (m, 1H), 2.38 (ddd, J = 13.4, 6.0, 4.1 Hz, 1H), 2.45 (s, 3H), 3.78 (dd, J = 12.0, 3.5 Hz,
1H), 3.84 (dd, J = 12.0, 2.9 Hz, 1H), 3.99 (dd, J = 6.3, 3.0 Hz, 1H), 4.37-4.53(m, 1H), 6.31 (t,
J = 6.4 Hz, 1H), 7.23 (s, 1H), 7.39 (d, J = 7.8 Hz, 2H), 7.69 (d, J = 7.8 Hz, 2H), 8.31 (s, 1H);
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C NMR (MeOD-d4) δ 21.6, 41.8, 62.7, 72.0, 87.0, 89.3, 109.7, 129.1, 131.0, 136.0, 138.3,
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142.0, 143.9, 146.8, 151.3, 161.6; HRMS calcd for C18H1935ClN2NaO7S [M+Na]+ 465.0494,
found 465.0493
(E)-5-(1-Chloro-2-tosylvinyl)uridine (10). Treatment of 5-ethynyluridine 7 (54 mg, 0.2
mmol) with p-toluenesulfonyl hydrazide (80 mg, 0.4 mmol) in the presence of FeCl3·6H2O
(108 mg, 0.4 mmol) by procedure A (column chromatography; CHCl3/MeOH; 95:5 → 90:10)
gave 10 (54 mg, 59%): UV (MeOH) λmax 242, 276 nm (ε 14 100, 10 800), λmin 230, 261 nm
(ε 13 200, 10 200); 1H NMR (DMSO-d6) δ 2.41 (s, 3H), 3.58 (ddd, J = 12.0, 5.0, 3.1 Hz, 1H),
3.67 (ddd, J = 11.9, 4.9, 3.1 Hz, 1H), 3.90 (q, J = 3.2 Hz, 1H), 4.01 (q, J = 4.9 Hz, 1H), 4.07
(q, J = 5.0 Hz, 1H), 5.14 (d, J = 5.0 Hz, 1H), 5.47 (d, J = 5.6 Hz, 1H), 5.80 (d, J = 4.8 Hz,
1H), 7.42 (d, J = 8.1 Hz, 2H), 7.53 (s, 1H), 7.57-7.79 (m, 2H), 8.25 (s, 1H), 11.67 (s, 1H); 13C
NMR (DMSO-d6) δ 21.1, 60.5, 69.5, 74.1, 79.1, 85.0, 88.5, 108.8, 127.6, 129.8, 134.0, 136.9,
139.6, 141.5, 144.8, 149.8, 159.4; HRMS calcd for: C18H1935ClN2O8S [M+H]+ for 459.0623,
found 459.0620.
(E)-5-(1-Bromo-2-tosylvinyl)uridine (11). Treatment of 7 (54 mg, 0.2 mmol) with ptoluenesulfonyl hydrazide (80 mg, 0.4 mmol) in the presence of FeBr3 (36 mg, 0.2 mmol) and
column chromatography; CHCl3/MeOH, 95:5 → 90:10) gave 11 (41.3 mg, 41%): UV
(MeOH) λmax 239, 277 nm (ε 13 500, 10 200), λmin 232, 264 nm (ε 12 800, 9600); 1H NMR
(DMSO-d6) δ 2.4 (s, 3H), 3.54-3.72 (m, 2H), 3.88-3.93 (m,1H), 3.96-4.1 (m, 2H), 5.1-5.2 (m,
2H), 5.48 (d, J = 5.6 Hz, 1H), 5.8 (d, J = 4.6 Hz, 1H), 7.43 (d, J = 7.9 Hz, 2H), 7.65 (S, 1H),
7.68 (d, J = 7.5 Hz, 2H), 8.22 (s, 1H), 11.68 (s, 1H); 13C NMR (DMSO-d6) δ 21.1, 60.5, 69.6,
74.2, 85.0, 88.5, 110.4, 127.7, 129.3, 129.8, 136.7, 136.9, 140.7, 144.8, 149.7, 159.3; HRMS
calcd for C18H19 81BrN2NaO8S [M+Na]+ 526.9917, found 526.9916.
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(E)-3',5'-Di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-deoxycytidine (19). Treatment of
3',5'-di-O-acetyl-5-ethynylcytidine 17 (156 mg, 0.465 mmol) with p-toluenesulfonyl
hydrazide (261 mg, 1.39 mmol) in the presence of FeCl3·6H2O (252 mg, 0.93 mmol) by
procedure A (column chromatography; CHCl3/MeOH; 100:0 → 90:5) gave 19 (168 mg,
68%): 1H NMR (DMSO-d6) δ 1.97 (s, 3H), 2.08 (s, 3H), 2.28-2.35 (m, 2H), 2.40 (s, 3H),
4.15-4.26 (m, 3H), 5.18 (br, 1H), 6.12 (br, 1H), 7.40 (d, J = 6.8 Hz, 2H), 7.65 (d, J = 7.1 Hz,
2H), 7.70 (s, 1H), 7.80 (s, 1H);
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C NMR (DMSO-d6) δ 20.3, 20.7, 21.0, 38.5, 63.0, 74.0,

75.0, 81.5, 86.0, 101.0, 127.5, 130.0, 136.0, 136.3, 141.2, 145.0, 147.0, 159.5, 169.5, 170.0.
HRMS calcd for C22H2535ClN3O8S [M+H]+ for 526.1051, found 526.1046
(E)-2',3',5'-Tri-O-acetyl-5-(1-chloro-2-tosylvinyl)cytidine (20). Treatment of 3',5'-di-Oacetyl-5-ethynylcytidine 18 (66 mg, 0.167 mmol) with p-toluenesulfonyl hydrazide (90 mg,
0.5 mmol) in the presence of FeCl3·6H2O (91 mg, 0.33 mmol) by procedure A (column
chromatography; CHCl3/MeOH; 100:0 → 90:5) gave 20 (48 mg, 60%): 1H NMR (CDCl3) δ
2.10 (s, 3H), 2.14 (s, 3H), 2.16 (s, 3H), 2.40 (s, 3H), 4.38-4.48 (m, 3H), 5.38 (dd, J = 10.1, 5.5
Hz, 1H), 5.49 (t, J = 5.2 Hz, 1H), 6.06 (d, J = 5.3 Hz, 1H), 7.10 (s, 1H), 7.32 (d, J = 8.2 Hz,
2H), 7.68 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H); 13C NMR (CDCl3) δ 20.4, 20.5, 20.8, 21.8, 63.0,
70.0, 74.0, 80.0, 89.5, 101.0, 128.0, 131.0, 136.0, 137.5, 139.5, 144.0, 146.0, 153.0, 160.5,
169.5, 169.7, 170.5
(E)-5-(1-Iodo-2-tosylvinyl)uridine (12). 5-Ethynyluridine 7 (26.8 mg, 0.1 mmol) was
dissolved in 5 mL THF.Then sodium p-toluenesulfinate (35.6 mg, 0.2 mmol) and NIS (23 mg,
0.1 mmol) were sequentially added into the solution and the resulting mixtures were stirred at
64 oC for 4 h. Volatiles were evaporated and column chromatography; CHCl3/MeOH; 95:5 →
90:10) gave 12 (21.5 mg, 42%): UV (MeOH) λmax 235, 262, 291 (sh) nm (ε 14 150, 12 650),
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λmin 220, 252 nm (ε 13 100, 12 400); 1H NMR (DMSO d6) δ 2.4 (s, 3H), 3.54-3.70 (m, 2H),
3.87-3.92 (m, 1H), 3.97-4.09 (m, 2H), 5.8 (d, J = 4.9 Hz, 1H), 7.4 (d, J = 8.1 Hz, 2H), 7.65 (d,
J = 8.3 Hz, 2H), 7.72 (s, 1H), 8.07 (s, 1H), 11.6 (s, 1H); 13C NMR (DMSO-d6) δ 21.1, 60.7,
69.7, 74.1, 85.1, 88.4, 99.5, 111.4, 127.6, 129.8, 136.7, 138.3, 142.6, 144.6, 149.8, 159.2;
HRMS calculated for C18H19IN2NaO8S [M+Na]+ 572.9799, found 572.9798.
β-Substituted analogues after displacement of halogen via addition-elimination
reaction (26-29, 32-33). Procedure B. Chlorovinyl sulfone analogues were dissolved in
methanol. Then methanolic ammonia, or thiol nucleophilic sources with triethyl amine was
added into the solution and the resulting mixtures were stirred at ambient temperature. The
volatiles were evaporated and the residue was column chromatographed to afford (26-29, 3233).
(E)-5-(1-(propylthio)-2-tosylvinyl)-2'-deoxyuridine (26). Treatment of 9 (30 mg, 0.07
mmol) with n-Propanethiol (7.4 µL, 6.2 mg, 0.08 mmol) in the presence of Et3N (11.3 µL, 8.2
mg, 0.08 mmol) for 2 h following the procedure B (column chromatography; CHCl3: MeOH =
95:5 → 90:10) gave E-26 (22 mg, 68%). UV (MeOH) λmax = 275 nm; 1H NMR (400 MHz,
DMSO-d6) δ 0.93 (t, J = 7.3 Hz, 3H) 1.47-1.64 (m, 2H), 2.00-2.11 (m, 1H), 2.14-2.19 (m,
1H), 2.39 (s, 3H), 2.80 (t, J = 7.2 Hz, 2H), 3.55 (dd, J = 3.5, 7.9 Hz, 2H), 3.82 (dd, J = 3.04,
6.04 Hz, 1H), 4.22-4.26 (m, 1H), 5.00 (t, J = 4.9 Hz, 1H), 5.27 (d, J = 4.2 Hz, 1H), 6.17 (t, J =
6.7 Hz, 1H), 6.46 (s, 1H), 7.38 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.89 (s, 1H),
11.51 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 13.2, 20.6, 21.1, 33.6, 61.2, 70.4, 84.6, 87.7,
122.3, 127.0, 129.5, 138.8, 143.7, 149.8, 160.1; HRMS calcd for C21H26N2NaO7S2 [M + Na]+
505.1074, found 505.1077.
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(E)-5-(1-Propylthio-2-tosylvinyl)uridine (27). Treatment of 10 (48 mg, 0.1 mmol) with
n-propanethiol (11 μL, 9 mg, 0.12 mmol) in the presence of Et3N (17 μL, 12 mg, 0.12 mmol)
for 2 h following the procedure B and column chromatography (CHCl3/MeOH, 95:5 → 9:1)
gave 27 (38 mg, 75%) as white solid: 1H NMR (DMSO-d6) δ 0.95 (t, J = 7.8 Hz, 3H), 1.55
(m, 2H), 2.40 (s, 3H), 2.80 (t, J = 7.8 Hz, 2H), 3.52-3.68 (m, 2H), 3.90 (m, 1H), 3.95-4.07 (m,
2H), 5.04 (brs, 1H) 5.15 (brs, 1H), 5.45 (d, J = 5.8 Hz, 1H), 5.80 (d, J = 5.1 Hz, 1H), 7.38 (d,
J = 8.1 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.96 (s, 1H), 8.32 (s, 1H), 11.45 (s, 1H); 13C NMR
(DMSO-d6) δ 13.2, 20.6, 21.1, 33.6, 60.7, 69.8, 74.0, 85.0, 88.2, 109.2, 122.1, 127.1, 128.4,
129.5, 138.2, 138.8, 143.6, 150.1, 160.1; HRMS calculated for C21H26N2NaO8S2 [M+Na]+
521.1023, found 521.1019.
S-[(E)-1-(2'-Deoxyuridin-5-yl)-2-tosylvinyl]-L-cysteine ethyl ester (28). Treatment of 9
(30 mg, 0.07 mmol) with L-cysteine ethyl ester hydrogen chloride (36 mg, 0.02 mmol, 3 eq.)
in the presence of Et3N (11.3 µL, 8.2 mg, 0.08 mmol, 1.2 eq.) for 2 h following the procedure
B (column chromatography; CHCl3: MeOH = 95:5 → 90 : 10) gave 28 (27 mg, 70 %, E/Z,
80:20) as a mixture of region isomers and further purification gave 28 (19 mg, 50 %) as single
isomer. 1H NMR (400 MHz, MeOD-d4) δ 1.32 (t, J = 7.2 Hz, 3H), 2.14 (ddd, J = 5.9, 7.3, 13.5
Hz, 1H), 2.30 (ddd, J = 3.1, 6.2, 13.6 Hz, 1H), 2.43 (s, 3H), 3.02 (dd, J = 7.8, 10.5 Hz, 1H),
3.12 (dd, J = 5.6, 10.5 Hz, 1H), 3.76 (dd, J = 3.7, 11.9 Hz, 1H), 3.83 (dd, J = 3.6, 11.9 Hz,
1H), 3.99 (d, J = 14.9 Hz, 1H), 4.03 (q, J = 3.4 Hz, 1H), 4.08 (dd, J = 5.6, 7.8 Hz, 1H), 4.27
(q, J = 7.1 Hz, 2H), 4.38 (dt, J = 3.0, 6.0 Hz, 1H), 4.75 (d, J = 14.9 Hz, 1H), 6.24 (t, J = 6.7
Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.99 (s, 1H); 13C NMR (100 MHz,
MeOD-d4) δ 14.5, 21.7, 37.1, 41.7, 62.8, 63.3, 63.6, 67.1, 72.7, 74.5, 87.0, 89.4, 116.4, 130.0,
130.9, 137.1, 138.1, 146.5, 151.6, 163.6, 172.8;
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C NMR (101 MHz, MeOD) δ 172.77,
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163.62, 151.64, 146.47, 138.11, 137.10, 130.89, 129.98, 116.37, 89.40, 87.01, 74.51, 72.73,
67.13, 63.64, 63.30, 62.79, 41.73, 37.08, 21.66, 14.47; HRMS calcd for C23H29N3NaO9S2
[M+Na]+ for 578.1237, found 578.1239
S-[(E)-1-(Uridin-5-yl)-2-tosylvinyl]-L-cysteine ethyl ester (29). Treatment of 10 (19
mg, 0.04 mmol) with L-cysteine ethyl ester hydrogen chloride (22.8 mg, 0.12 mmol) in the
presence of Et3N (45.7 μL, 33.2 mg, 0.32 mmol) for 2 h following the procedure B and
column chromatography; CHCl3/MeOH, 95:5 → 9:1) gave 29 (E/Z, 85:15; 13 mg, 56%) as
white solid. The E-isomer had: 1H NMR (DMSO-d6) δ1.20 (t, J = 7.2 Hz, 3H), 2.40 (s, 3H),
2.95 (dd, J = 10.5, 7.8 Hz, 1H), 3.09 (dd, J = 10.5, 5.6 Hz, 1H), 3.53-3.58 (m, 2H), 3.61-3.63
(m, 1H), 3.87-3.90 (m, 1H), 3.95–4.00 (m, 2H), 4.04–4.12 (m, 4H), 5.00-5.20 (m, 2H), 5.45
(d, J = 5.7 Hz, 1H), 5.80 (d, J = 5.1 Hz, 1H), 6.58 (s, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.68 (d, J
= 8.3 Hz, 2H), 7.96 (s, 1H), 11.50 (s, 1H); 13C NMR (DMSO-d6) δ 14.0, 21.0, 37.0, 53.5,
61.5, 61.6, 69.5, 74.0, 85.0, 88.5, 96.0, 116.0, 122.5, 127.5, 128.5, 129.5, 138.5, 143.5, 150.5,
160.0, 173.0; HRMS calculated for C23H29N3NaO10S2 [M+Na]+ 594.1187, found 594.1173.
S-[(E)-1-(2'-Deoxyuridin-5-yl)-2-tosylvinyl]-L-glutathione

(30).

The

5-(β-

chloro)vinyl sulfone analogue 9 (25 mg, 0.056 mmol) was dissolved in 1 mL methanol-water
(80:20) cosolvent system. Then, L-glutathione (25.8 mg, 0.084 mmol) and Et3N (59.0 μL,
42.5 mg, 0.42 mmol) were sequentially added and the resulting mixtures were stirred at
ambient temperature for 4 h. The volatile were evaporated and reverse phase HPLC separation
gave 30 (22 mg, 55%) as white solid. 1H NMR (D2O) δ 2.15 (q, J = 7.2 Hz, 2H), 2.27-2.39
(m, 2H) 2.45 (s, 3H), 2.50 (t, J = 7.5 Hz, 2H), 3.24-3.45 (m, 2H), 3.70-3.80 (m, 3H), 3.854.02 (m, 2H), 4.08 (br, 1H), 4.50 (br, 1H), 4.60-4.70 (m, 2H), 6.25 (t, J = 6.7 Hz, 1H), 6.85 (s,
1H), 7.42 (d, J = 8.1 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.70 (s, 1H); 13C NMR (D2O) δ 21.0,
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26.4, 31.0, 33.0, 39.5, 43.8, 52.0, 54.0, 61.0, 70.0, 85.5, 94.0, 108.0, 126.0, 130.0, 135.0,
136.0, 142.0, 145.8, 151.0, 159.8, 170.7, 174.0, 175.0, 176.2; HRMS calculated for
C28H35N5O16PS2 [M-H]- 792.12633, found 792.121640

(Z)-5-(1-Amino-2-tosylvinyl)uridine (32). Treatment (2 h) of 10 (25 mg, 0.054 mmol)
with NH3/MeOH (3 mL) by the procedure B and column chromatography; CHCl3/MeOH,
9:1) gave 32 (20 mg, 84%): 1H NMR (DMSO-d6) δ 2.37 (s, 3H), 3.59 (ddd, J = 2.8, 5.3, 12.3
Hz, 1H), 3.68 (ddd, J = 3.0, 5.0, 12.3 Hz, 1H), 3.86-3.8 (m, 1H), 4.00 (q, J = 5.19 Hz, 1H),
4.10-4.14 (m, 2H), 5.11 (d, J = 5.6 Hz, 1H), 5.21 (s, 1H) ,5.29 (t, J = 5.1 Hz, 1H), 5.44 (d, J =
5.4 Hz, 1H), 5.72 (d, J = 4.2 Hz, 1H), 6.99 (s, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.76 (d, J = 8.2
Hz, 2H), 8.33 (s, 1H), 11.66 (s, 1H); 13C NMR (DMSO-d6) δ 20.9, 60.2, 69.1, 73.9, 84.8,
88.2, 89.1, 107.2, 125.5, 129.4, 141.5, 142.2, 142.3, 149.4, 150.7, 161.6; HRMS calculated for
C18H22N3O8S [M+H]+ 440.1122, found 440.1100.
5-[1-(n-Aminobutyl)-2-tosylvinyl]uridine (33). Treatment of β-chlorovinyl analogue 10
(25 mg, 0.054 mmol) with n-butyl amine 27 μL, 20 mg, 0.27mmol) for 5 h following the
procedure B and column chromatography; CHCl3/MeOH, 95:5 → 90:10) gave 33 (19 mg,
71%) as E/Z mixtures (85:15). The major isomer had: 1H NMR (MeOH-d4) δ 0.85 (t, J = 7.5
Hz, 3H), 1.40 (sex, J = 7.2 Hz, 2H), 1.58 (quin, J = 7.5 Hz, 2H), 2.40 (s, 3H), 3.00 (t, J = 7.0
Hz, 2H), 3.75 (dd, J = 10.3, 6.0 Hz, 1H), 3.82 (dd, J = 10.2, 5.8 Hz, 1H), 4.0-4.05 (m, 1H),
4.20 (ddd, J = 9.4, 6.4, 2.3 Hz, 1H), 4.25 (dd, J = 9.7, 4.6 Hz, 1H), 5.00 (s, 1H), 5.9 (d, J =
4.5 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.95(s, 1H).
(E)-5-(2-Tosylvinyl)uridine (36). Step a. p-Toluenesulfonic acid (62 mg, 0.4 mmol) was
added to a solution of 2',3',5'-tri-O-acetyl-5-ethynyluridine 5 (68 mg, 0.17 mmol) in dry THF
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(3 mL) containing Cu(OAc)2•2H2O (3 mg, 0.015 mmol) under nitrogen at ambient
temperature. The resulting solution was stirred at 60 oC (oil bath) for 7 h. After cooling to
ambient temperature, the volatiles were evaporated under the reduced pressure and the residue
was column chromatographed (hexane/EtOAc, 1:1→4:6) to give (E)-2',3',5'-tri-O-acetyl-5-(2tosylvinyl)uridine (31.5 mg, 35%): 1H NMR δ 2.10 (s, 3H), 2.12 (s, 2H), 2.21 (s, 3H), 2.42 (s,
3H), 4.30 – 4.51 (m, 3H), 5.31 (t, J = 5.3 Hz, 1H), 5.36 (t, J = 5.2 Hz, 1H), 6.00 (d, J = 4.8
Hz, 1H), 7.19 (d, J = 15.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 15.0 Hz, 1H), 7.76
(d, J = 8.2 Hz, 2H), 7.79 (s, 1H), 8.70 (s, 1H). Step b. Methanolic ammonia (1.5 mL) was
added to the solution of the material (25.5 mg, 0.045 mmol) in MeOH (1.5 mL) at 0 oC and
the resulting solution was stirred for overnight. Volatiles were evaporated and the residue was
column chromatographed (CHCl3/MeOH, 9:1) to give 36 (12 mg, 63%): 1H NMR (MeODd4) δ 2.42 (s, 3H), 3.77 (dd, J = 12.4, 2.6 Hz, 1H), 3.93 (dd, J = 12.4, 2.6 Hz, 1H), 4.02 (dt, J
= 5.2, 2.6 Hz, 1H), 4.12 – 4.21 (m, 2H), 5.87 (d, J = 3.1 Hz, 1H), 7.30 (d, J = 15.0 Hz, 1H),
7.39 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 15.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 8.61 (s, 1H); 13C
NMR (MeOD-d4) δ 21.5, 61.5, 70.4, 76.2, 86.2, 91.3, 108.7, 128.2, 128.5, 131.1, 136.2,
139.6, 145.8, 146.6, 151.1, 163.3. HRMS calculated for C18H20N2NaO8S [M+Na]+ 447.0833,
found 447.0802.
Synthesis of protected 5-(β-keto sulfone) of uracil nucleoside (49, 50a and 50b).
General Procedure C. Protected 5-ethylnyluracil nucleosides were taken in a round bottom
flask and dissolved in 1, 2 dichloroethane. Then freshly prepared p-toluenesulfinic acid and
pyridine were sequentially added into the solution. A balloon filled with oxygen was
connected with the flask and the resulting mixtures were placed in an oil bath and stirred at 45
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C for 4 h. The reaction mixtures were washed with dil. HCl followed by NaHCO 3 solution.

The organic layer was column chromatographed to afford (35, 50a, and 50b).
1-N-benzyl-5-(2-tosylacetyl)uracil (49). Treatment of 1-N-benzyl-5-ethynyluracil 48
(45.2 mg, 0.2 mmol) with p-toluenesulfinic acid (156 mg, 1.0 mmol) and pyridine (66 μL,
64.9 mg, 0.82 mmol) in the presence of oxygen (balloon) by procedure C and column
chromatography (Hexane : EtOAc = 1:1) gave 49 (35 mg, 44%) as white solid. 1H NMR δ
2.42 (s, 3H), 4.98 (s, 4H), 7.29 (d, J = 8.0 Hz, 2H), 7.34-7.31 (m, 2H), 7.45-7.37 (m, 3H), 7.79
(d, J = 8.3 Hz, 2H), 8.23 (s, 1H), 8.46 (s, 1H); 13C NMR δ 21.8, 52.9, 65.4, 112.0, 128.58,
128.61, 129.4, 129.6, 129.9, 133.9, 137.0, 145.3, 149.6, 151.7, 160.5, 183.8; HRMS calcd for
C20H19N2O5S [M + H]+ 399.1009, found 399.1017.
3',5'-Di-O-acetyl-5-(2-tosylacetyl)-2'-deoxyuridine (50a) Treatment of protected 5ethynyl-2'-deoxyuridne 4 (25 mg, 0.074 mmol) with p-toluenesufinic acid (58 mg,
0.372mmol) and pyridine (14.5 μL, 14.2 mg, 0.372 mmol) in the presence of oxygen (balloon)
by procedure C and column chromatography (Hexane/EA ; 60:40 → 40:60) gave 50a (6 mg,
16%) as white solid: 1H NMR (CDCl3) δ 2.13(s, 3H), 2.16 (s, 3H), 2.45 (s, 3H), 2.58-2.66 (m,
1H), 2.74-2.78 ( m, 1H), 4.35 (dd, J = 6.9, 3.8 Hz, 1H), 4.36-4.40 (m, 2H), 4.93 (d, J = 13.0
Hz, 1H), 5.04 (d, J = 13.1 Hz, 1H), 5.24-5.30 (m, 1H), 6.35 (dd, J = 11.9, 6.4 Hz, 1H), 7.35
(d, J = 7.8 Hz, 2H), 7.70 (d, J = 8.1 Hz, 2H), 8.40 (s, 1H), 8.60 (s, 1H).
2',3',5'-Tri-O-acetyl-5-(2-tosylacetyl)uridine

(50b)

Treatment

of

protected

5-

ethynyluridine 5 (36 mg, 0.09 mmol) with p-toluenesufinic acid (78 mg, 0.5 mmol) and
pyridine (40 μL, 39.2 mg, 0.5 mmol) in the presence of air (balloon) and column
chromatography (Hexane/EA ; 60:40 → 40:60) gave 50b (9 mg, 20%) as white solid: 1H
NMR (CDCl3) δ 2.11(s, 3H), 2.14 (s, 3H), 2.19 (s, 3H), 2.45 (s, 3H), 4.35 (ddd, J = 12.1, 6.9,
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3.8 Hz, 2H), 4.40-4.44 (m, 1H), 4.93 (d, J = 13.3 Hz, 1H), 5.06 (d, J = 13.3 Hz, 1H), 5.335.38 (m, 1H), 6.35 (d, J = 4.5 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 8.50
(s, 1H), 8.65 (s, 1H)
5-(2-Tosylacetyl)uracil/cytosine nucleosides (51-52 and 58-59). Procedure D.
Acetyl protected (8 and 19-20) or unprotected (9-10) 5-(1-chloro-2-tosylvinyl)pyrimidine
nucleosides were dissolved in methanolic ammonia and the resulting mixtures were stirred at
0 oC → r.t; The volatiles were evaporated and the residue was dissolved in 4 mL CH 3CN. The
solution was acidified (pH ~ 4) by adding dil. HCl (aq) and stirred for 2h. After neutralizing
the solution with dil. NaOH(aq), the volatiles were evaporated and the residue was column
chromatographed to give the products (51-52 and 58-59).
5-(2-Tosylacetyl)-2'-deoxyuridine (51). Treatment of 9 (96 mg, 0.21 mmol) with
methanolic ammonia (3 mL) for 2 h and subsequent acid hydrolysis as described in procedure
D followed by column chromatography (CHCl3/MeOH ; 100:0 → 95:5) gave 51 (68 mg,
72%) as white solid: 1H NMR (DMSO-d6) δ 2.10-2.27 (m, 2H, H2',2"), 2.40 (s, 3, Me), 3.513.63 (m, 2H, H5',5"), 3.87 (q, J = 3.1 Hz, 1H, H4'), 4.23 (q, J = 3.4 Hz, 1H, H3'), 5.10 (t, J =
4.5 Hz, 1H, 5'OH), 5.15 (s, 2H, α-CH2), 5.30 (d, J = 4.1 Hz, 1H, 3'OH), 6.06 (t, J = 6.3 Hz,
1H, H1'), 7.42 (d, J = 8.2 Hz, 2H, Ar), 7.74 (d, J = 8.1 Hz, 2H, Ar), 8.68 (s, 1H, H6), 11.80 (s,
1H, NH); 13C NMR (DMSO-d6) δ 21.0, 41.0, 60.5, 64.0, 70.0, 86.0, 88.0, 110.5, 128.0, 130.0,
137.0, 144.0, 148.0, 149.0, 161.0, 184.0; HRMS calcd for C18H20N2NaO8S [M+Na]+ for
447.0833, found 447.0874
5-(2-Tosylacetyl)uridine (52). Treatment of 10 (96 mg, 0.21 mmol) with methanolic
ammonia (3 mL) for 2 h and subsequent acid hydrolysis as described in procedure D followed
by column chromatography (CHCl3/MeOH ; 100:0 → 95:5) gave 52 (65 mg, 70%) as white
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solid: 1H NMR (DMSO-d6) δ 2.40 (s, 3H, Me), 3.55-3.75 (m, , 1H, H5'5"), 3.93 (q, J = 3.2
Hz, 1H, H4'), 3.95 (t, J = 4.9 Hz, 1H, H3'), 4.08 (t, J = 5.0 Hz, 1H, H2'), 5.12 (t, J = 4.5 Hz,
1H, 5'OH), 5.14 (s, 2H, α-CH2), 5.21 (d, J = 4.1 Hz, 1H, 3'OH), 5.51 (d, J = 4.9 Hz, 1H,
2'OH), 5.75 (d, J = 2.2 Hz, 1H, H1'), 7.42 (d, J = 7.8 Hz, 2H, Ar), 7.74 ( d, J = 7.8 Hz, 2H,
Ar), 8.80 (s, 1H, H6), 11.85 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.0, 60.0, 64.2, 69.5, 75.0,
85.0, 89.5, 111.0, 128.0, 130.0, 137.0, 144.5, 148.0, 149.5, 161.0, 185.0
5-(2-Tosylacetyl)-2'-deoxycytidine (58). Treatment of acetyl protected (β-chloro) vinyl
sulfone 19 (150 mg, 0.28 mmol) with methanolic ammonia (5 mL) for 12 h and subsequent
acid hydrolysis as described in procedure D followed by column chromatography
(CHCl3/MeOH ; 100:0 → 95:10) gave 58 (70 mg, 59%) as white solid: 1H NMR (DMSO-d6)
δ 2.05-2.10 (m, 1H, H2'), 2.30 (ddd, J = 13.2, 8.2, 2.1 Hz, 1H, H2"), 2.40 (s, 3H, Me), 3.623.68 (m, 1H, H5'), 3.70-3.76 (m, 1H, H5"), 3.92 (q, J = 3.4 Hz, 1H, H4'), 4.30 (quint, J = 4.6
Hz, 1H, H3'), 4.86 (d, J = 14.1 Hz, 1H, α-CH), 4.95 (d, J = 14.1 Hz, 1H, α-CH), 5.29 (d, J =
4.4 Hz, 1H, 3'OH), 5.34 (t, J = 5.3 Hz, 1H, 5'OH), 6.09 (t, J = 5.9 Hz, 1H, H1'), 7.45 (d, J =
8.3 Hz, 2H, Ar), 7.75 ( d, J = 7.8 Hz, 2H, Ar), 8.10 (d, J = 5.4 Hz, 2H, NH2), 9.02 (s, 1H, H6);
C NMR (DMSO-d6) δ 21.0, 41.5, 61.0, 62.5, 69.5, 86.0, 88.0, 103.0, 128.0, 130.0, 136.0,
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144.5, 152.0, 152.5, 163.0, 185.5; HRMS calcd for C18H22N3O7S [M+H]+ 424.1178, found
424.1176
5-(2-Tosylacetyl)cytidine (59). Treatment of acetyl protected (β-chloro) vinyl sulfone 20
(35 mg, 0.06 mmol) with methanolic ammonia (4 mL) for 12 h and subsequent acid
hydrolysis as described in procedure D followed by column chromatography (CHCl3/MeOH ;
100:0 → 95:10) gave 59 (17 mg, 64%) as white solid: 1H NMR (DMSO-d6) δ 2.40 (s, 3H,
Me), 3.68 (ddd, J = 12.5, 5.2, 3.0 Hz, 1H, H5'), 3.85 (ddd, J = 12.1, 4.5, 2.3 Hz, 1H, H5"),
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3.95 (q, J = 3.4 Hz, 1H, H4'), 3.98-4.02 (m, 1H, H3') 4.03-4.09 (m, 1H, H2'), 4.80 (d, J = 14.1
Hz, 1H, α-CH), 4.95 (d, J = 14.1 Hz, 1H, α-CH), 5.05 (d, J = 6.5 Hz, 1H, 3'OH), 5.45 (t, J =
5.0 Hz, 1H, 5'OH), 5.58 (d, J = 4.8 Hz, 1H, 2'OH), 5.71 (d, J = 1.9 Hz, 1H, H1'), 7.43 (d, J =
8.3 Hz, 2H, Ar), 7.74 ( d, J = 8.2 Hz, 2H, Ar), 8.06 (d, J = 3.2 Hz, 1H, NH), 8.13 (d, J = 3.2
Hz, 1H, NH), 9.05 (s, 1H, H6);

13

C NMR (DMSO-d6) δ 21.0, 60.0, 62.5, 68.3, 74.0, 84.0,

91.0, 103.5, 128.0, 130.0, 136.0, 145.0, 152.0, 152.5, 162.5, 185.5
Incorporation of electrophiles at the α-carbon of β-keto sulfone moiety of
pyridmidine nucleoside analogues (53-56 and 60-62). Procedure E. 5-(β-keto)sulfones of
uracil/cytosine nucleoside were dissolved in 1 mL MeOH. Then 5M NaOH/H2O solution (2
equiv.) were added and the solution was stirred for 20 min. Finally, 1.2 equiv. of the
electrophile source (R-X) was added and the resulting solution was stirred at ambient
temperature. The solution was neutralized by adding dil. HCl and volatiles were evaporated.
The residue was column chromatographed to give the desired products (53-56 and 60-62).
5-(2-Benzyl-2-tosylacetyl)-2'-deoxyuridine (53). Treatment of 51 (18 mg, 0.042 mmol)
with NaOH(aq) (16 µL, 3.36 mg, 0.084 mmol), and benzyl bromide (10 µL, 14.4 mg, 0.05
mmol) for 3 h as described in procedure E followed by column chromatography
(CHCl3/MeOH; 100:0 → 95:5) gave 53 as a (50/50) mixture of diastereomers (6 mg, 28%)
along with byproducts. 1H NMR (DMSO-d6) δ 2.05-2.20 (m, 1.0, H2'), 2.22-2.32 (m, 1.0,
H2"), 2.40 (s, 1.5, Me), 2.41 (s, 1.5, Me), 3.25-3.30 (m, 1, Bn), 3.10-3.20 (m, 1.0, Bn), 3.543.68 (m, 2.0, H5',5"), 3.88 (q, J = 3.2 Hz, 1.0, H4'), 4.20 (dd, J = 9.2, 4.2 Hz, 0.5, H3'), 4.25
(dd, J = 9.2, 4.2 Hz, 0.5, H3'), 5.12-5.18 (m, 1.0, 5'OH), 5.28 (d, J = 4.3 Hz, 0.5, 3'OH), 5.33
(d, J = 4.3 Hz, 0.5, 3'OH), 5.97 (t, J = 6.2 Hz, 0.5, H1'), 6.06 (t, J = 6.3 Hz, 0.5, H1'), 6.52 (t,
J = 3.4 Hz, 0.5, α-CH ), 6.56 (t, J = 3.4 Hz, 0.5, α-CH), 7.05 (d, J = 7.1 Hz, 2.0, Ar) 7.13 (t, J
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= 6.5 Hz, 1.0, Ar), 7.18 (t, J = 6.9 Hz, 2.0, Bn) 7.42 (d, J = 7.9 Hz, 1.0, Ar), 7.44 (d, J = 7.9
Hz, 1.0, Ar), 7.67 (d, J = 8.1 Hz, 1.0, Ar), 7.69 (d, J = 8.1 Hz, 1.0, Ar), 8.63 (s, 0.5, H6), 8.70
(s, 0.5, H6), 11.50 (s, 1.0, NH);

13

C NMR (DMSO-d6) δ 21.0, 31.3, 31.6, 40.5, 40.9, 54.8,

60.7, 60.8, 69.9, 86.0, 86.5, 88.0, 88.2, 111.0, 111.4, 126.6, 128.4, 128.5, 128.6, 128.8, 128.9,
129.6, 129.8, 134.5, 136.1, 136.2, 145.0, 145.1, 148.0, 148.1, 149.1, 149.2, 161.4, 161.5,
186.1, 186.2; HRMS calcd for C25H27N2O8S [M+H]+ 515.1488, found 515.1437
5-(2-Methyl-2-tosylacetyl)-2'-deoxyuridine (54). Treatment of 51 (16 mg, 0.037 mmol)
with NaOH(aq) (16 µL, 2.96 mg, 0.074 mmol), and methyl iodide (4.60 µL, 10.50 mg, 0.074
mmol) for 4 h as described in procedure E followed by column chromatography
(CHCl3/MeOH; 100:0 → 95:5) gave 54 as a (50/50) mixture of diastereomers (5 mg, 31%)
and two byproducts. 1H NMR (DMSO-d6) δ 1.32 (t, J = 7.4 Hz, 3.0), 2.10-2.18 (m, 1.0, H2'),
2.20-2.30 (m, 1.0, H2"), 2.39 (s, 1.5, Me), 2.40 (s, 1.5, Me), 3.53-3.64 (m, 2.0, H5',5"), 3.873.92 (m, 1H, H4'), 4.21-4.29 (m, 1.0, H3'), 5.11-5.16 (m, 1.0, 5'OH), 5.30 (d, J = 4.3 Hz, 0.5,
3'OH), 5.33 (d, J = 4.3 Hz, 0.5, 3'OH), 5.97 (q, J = 6.5 Hz, 1.0, α-CH), 6.05 (t, J = 6.3 Hz, 0.5,
H1' ), 6.11 (t, J = 6.4 Hz, 0.5, H1'), 7.42 (t, J = 7.6 Hz, 2.0, Ar), 7.65 (d, J = 8.1 Hz, 1.0, Ar),
7.68 (d, J = 8.1 Hz, 1.0, Ar), 8.71 (s, 0.5, H6), 8.73 (s, 0.5, H6), 11.80 (s, 1.0, NH); 13C NMR
(DMSO-d6) δ 11.0, 11.2, 21.1, 40.8, 41.0, 60.8, 60.9, 65.5, 70.0, 86.0, 86.5, 88.0, 88.1, 111.0,
111.2, 128.8, 128.9, 129.6, 129.8, 145.0, 145.1, 148.0, 148.1, 149.1, 149.2, 161.3, 161.4,
186.1, 187.8
5-(2-Allyl-2-tosylacetyl)-2'-deoxyuridine (55). Treatment of 51 (18 mg, 0.042 mmol)
with NaOH(aq) (16 µL, 3.36 mg, 0.084 mmol), and Allyl bromide (6 µL, 8.38 mg, 0.069
mmol) for 4 h as described in procedure E followed by column chromatography (CHCl3/
MeOH; 100:0 → 95:5) gave 55 as a (52/48) mixture of diastereomers (6 mg, 31%) and two
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byproducts: 1H NMR (DMSO-d6) δ 2.05-2.20 (m, 1.10, H2'), 2.22-2.35 (m, 0.90, H2"), 2.39
(s, 1.65, Me), 2.40 (s, 1.35, Me), 2.66-2.78 (m, 2.00, CH2), 3.56-3.53-3.68 (m, 2.00, H5',5"),
3.89 (q, J = 3.3 Hz, 1.00, H4'), 4.21-4.29 (m, 1.00, H3'), 4.93-5.01 (m, 1.65, allyl), 5.11-5.17
(m, 1.00, 5'OH), 5.30 (d, J = 4.3 Hz, 0.55, 3'OH), 5.35 (d, J = 4.3 Hz, 0.45, 3'OH), 5.55-5.66
(m, 1.00, allyl), 6.05 (t, J = 6.2 Hz, 0.45, H1'), 6.10 (t, J = 6.2 Hz, 0.55, H1'), 6.18 (d, J = 2.6
Hz, 0.55, α-CH), 6.21 (d, J = 2.6 Hz, 0.45, α-CH), 7.40 (d, J = 8.2 Hz, 1.10, Ar), 7.44 (d, J =
8.2 Hz, 0.90, Ar), 7.65 (d, J = 7.5 Hz, 2.00, Ar), 8.71 (s, 0.45, H6), 8.73 (s, 0.55, H6), 11.80
(s, 1.00, NH); 13C NMR (DMSO-d6) δ 21.1, 30.0, 30.3, 40.5, 41.0, 60.8, 60.9, 68.9, 70.0, 70.1,
86.0, 86.5, 88.0, 88.1, 110.8, 111.2, 118.0, 129.0, 129.6, 129.9, 133.0, 134.5, 134.6, 148.0,
148.1, 149.0, 149.2, 161.5, 161.6, 186.5, 186.7
5-(2-Allyl-2-tosylacetyl)uridine (56). Treatment of 51 (18 mg, 0.04 mmol) with
NaOH(aq) (16 µL, 3.36 mg, 0.084 mmol), and allyl bromide (6 µL, 8.38 mg, 0.069 mmol) for
4 h as described in procedure E followed by column chromatography (CHCl3/ MeOH; 100:0
→ 95:5) gave 56 as a (52/48) mixture of diastereomers (6 mg, 32%) and two byproducts: 1H
NMR (DMSO-d6) δ 2.39 (s, 0.48, Me), 2.40 (s, 0.52, Me), 2.66-2.78 (m, 2.00, allyl), 3.573.63 (m, 0.96, H5'), 3.69-3.77 (m, 1.04, H5"), 3.4 (q, J = 3.3 Hz, 1.00, H4'), 3.95-4.02 (m,
1.00, H3'), 4.03-4.09 (m, 1.00, H2'), 4.93-5.01 (m, 1.04, allyl), 4.93-5.10 (m, 0.96, allyl), 5.13
(d, J = 5.3 Hz, 1.04, 3'OH), 5.20 (d, J = 5.4 Hz, 0.96, 3'OH), 5.23-5.28 (m, 1.00, 5'OH), 5.48
(d, J = 5.3 Hz, 0.48, 3'OH), 5.58 (d, J = 5.2 Hz, 0.52, 3'OH), 5.59-5.67 (m, 1.00, allyl), 5.71
(d, J = 3.7 Hz, 0.48, H1'), 5.78 (d, J = 4.0 Hz, 0.52, H1'), 6.13-6.21 (m, 1.00, α-CH), 7.42 (d,
J = 8.2 Hz, 0.96, Ar), 7.46 (d, J = 8.2 Hz, 1.04, Ar), 7.65 (d, J = 7.1 Hz, 2.00, Ar), 8.81 (s,
0.48, H6), 8.90 (s, 0.52, H6), 11.80 (s, 1.00, NH);

C NMR (DMSO-d6) δ 21.1, 30.0, 30.1,
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60.0, 60.2, 68.8, 69.0, 69.2, 69.6, 74.4, 74.6, 85.0, 85.3, 89.2, 89.6, 111.2, 111.4, 117.6,
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128.8, 129.0, 129.8, 130.0, 133.0, 135.4, 145.0, 148.5, 148.8, 149.4, 149.6, 161.4, 161.5,
186.7, 186.8
5-(2-Benzyl-2-tosylacetyl)-2'-deoxycytidine (60). Treatment of 58 (18 mg, 0.043 mmol)
with NaOH(aq) (11 µL, 2.2 mg, 0.055 mmol), and benzyl bromide (6.5 µL, 9.4 mg, 0.05
mmol) for 8 h as described in procedure E followed by column chromatography (CHCl3/
MeOH; 100: 0 → 95:5) gave 60 as a (52/48) mixture of diastereomers (15 mg, 68%). 1H
NMR (DMSO-d6) δ 1.93-2.03 (m, 1.04, H2'), 2.22-2.30 (m, 0.96, H2"), 2.38 (s, 1.42, Me),
2.41 (s, 1.58, Me), 3.20-3.30 (m, 2.00, Bn), 3.54-3.68 (m, 2.00, H5',5"), 3.89 (q, J = 3.5 Hz,
0.52, H4'), 4.00 (q, J = 3.5 Hz, 0.48, H4'), 4.20 (quint, J = 4.9 Hz, 0.52, H3'), 4.38 (quint, J =
4.7 Hz, 0.48, H3'), 5.28 (d, 0.52, J = 4.6 Hz, 3'OH), 5.35 (d, J = 4.3 Hz, 0.48, 3'OH), 5.48 (dd,
J = 11.3, 3.6 Hz, 0.48, α-CH), 5.58 (dd, J = 10.7, 4.4 Hz, 0.48, α-CH), ,5.68 (t, J = 4.6 Hz,
0.48, 5'OH), 5.75 (t, J = 4.9 Hz, 0.52, 5'OH), 5.94-6.20 (m, 1.00, H1' ), 7.08-7.23 (m, 5.00,
Bn), 7.42 (d, J = 8.2 Hz, 1.04, Ar), 7.46 (d, J = 8.2 Hz, 0.96, Ar), 7.67 (d, J = 9.7 Hz, 0.52,
Ar) 7.71 (d, J = 8.8 Hz, 0.48, Ar), 8.03 (d, J = 3.6 Hz, 0.52, NH2), 8.14 (d, J = 3.5 Hz, 0.48,
NH2), 8.92 (s, 0.48, H6), 9.06 (s, 0.52, H6);

13

C NMR (DMSO-d6) δ 21.0, 31.8, 32.2, 41.4,

41.6, 60.5, 60.8, 68.5, 69.0, 69.4, 69.6, 69.8, 86.0, 86.8, 87.6, 88.0, 104.0,104.8, 126.7, 126.9,
128.4, 128.5, 128.6, 128.7, 128.8, 128.9, 129.8, 129.9, 133.7, 133.8, 135.6, 135.8, 145.1,
145.3, 151.0, 151.2, 152.0, 162.0, 162.4, 187.4, 188.0
5-(2-Methyl-2-tosylacetyl)-2'-deoxycytidine (61). Treatment of 58 (18 mg, 0.043 mmol)
with NaOH(aq) (20 µL, 4.0 mg, 0.1 mmol), and benzyl bromide (7.5 µL, 9.4 mg, 0.086 mmol)
for 24 h as described in procedure E followed by column chromatography (CHCl3/ MeOH;
100: 0 → 95:5) gave 61 as a (52/48) mixture of diastereomers (15 mg, 68%).1H NMR
(DMSO-d6) δ 1.33 (d, J = 6.5 Hz, 1.44, CH3), 1.37 (d, J = 6.5 Hz, 1.56, CH3), 2.03-2.18 (m,
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0.96, H2'), 2.28-2.35 (m, 1.04, H2"), 2.40 (s, 3.00, Me), 3.60-3.95 (m, 2.00, H4' & H5'5"),
4.20 (quint, 0.52, H3'), 4.39 (q, J = 3.5 Hz, 0.52, H4'), 4.00 (q, J = 3.5 Hz, 0.48, H4'), 4.20
(quint, J = 4.8 Hz, 0.52, H3'), 4.39 (quint, J = 4.8 Hz, 0.48, H3'), 5.16-5.28 (m, 1.00, α-CH),
5.30-5.45 (m, 2.00, 3' & 5'OH), 6.00 (t, J = 4.8 Hz, 0.52, H1'), 6.15 (t, J = 5.5 Hz, 0.48, H1'),
7.42 (d, J = 7.8 Hz, 1.04, Ar), 7.46 (d, J = 7.8 Hz, 0.96, Ar), 7.62 (d, J = 8.2 Hz, 1.04, Ar),
7.66 (d, J = 8.2 Hz, 0.96, Ar), 8.05-8.12 (m, 0.52, NH2), 8.22 (d, J = 3.5 Hz, 0.48, NH2), 9.08
(s, 0.48, H6), 9.16 (s, 0.52, H6);

C NMR (DMSO-d6) δ 12.0, 21.0, 41.2, 41.4, 60.2, 60.5,

13

63.3, 64.1, 68.8, 69.0, , 86.0, 86.8, 87.6, 88.1, 104.0,104.5, 129.0, 129.2, 130.0, 130.5, 133.4,
133.7, 145.1, 145.3, 151.8, 152.0, 152.4, 162.8, 163.0, 189.0, 189.2
5-(2-Benzyl-2-tosylacetyl)cytidine (62). Treatment of 59 (15 mg, 0.034 mmol) with
NaOH(aq) (13.6 µL, 2.7 mg, 0.068 mmol), and benzyl bromide (8.5 µL, 11.6 mg, 0.068
mmol) for 8h as described in procedure E followed by column chromatography (CHCl3/
MeOH; 100: 0 → 95:5) gave 62 as a (54/46) mixture of diastereomers (12 mg, 67%). 1H
NMR (DMSO-d6) δ 2.38 (s, 1.62, Me), 2.40 (s, 1.38, Me), 3.15-3.30 (m, 2.00, Bn), 3.72-3.90
(m, 2.00, H5',5"), 3.91-3.97 (m, , 1.00, H4'), 3.98-4.03 (m, 1.00, H3'), 4.04-4.20 (m, 1.00,
H2'), 5.28 (d, J = 4.6 Hz, 0.54, 3'OH), 5.05 (d, J = 6.3 Hz, 0.46, 3'OH), 5.20 (d, J = 3.6 Hz,
0.54, 3'OH), 5.45-5.52 (m, 1.00, 2'OH ), 5.53-5.58 (m, 1.00, 1'), 5.59-5.63 (m, 1.00, α-CH),
5.72-5.88 (m, 1.00, 5'OH ), 7.09-7.23 (m, 5.00, Bn), 7.42 (d, J = 8.3 Hz, 1.08, Ar), 7.46 (d, J =
8.2 Hz, 0.92, Ar), 7.66 (d, J = 8.2 Hz, 1.08, Ar), 7.69 (d, J = 8.2 Hz, 0.92, Ar), 7.98-8.08 (m,
1.08, NH2), 8.15 (d, J = 3.6 Hz, 0.92, NH2), 8.90 (s, 0.54, H6), 9.06 (s, 0.46, H6);

13

C NMR

(DMSO-d6) δ 21.0, 31.8, 32.0, 59.4, 60.0, 67.5, 68.2, 68.3, 68.5, 69.2, 74.8, 75.0, 79.2, 83.8,
84.2, 90.6, 91.4, 104.1,104.7, 126.6, 126.9, 128.4, 128.5, 128.6, 128.7, 128.8, 128.9, 129.8,
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130.1, 133.7, 134.1, 135.6, 135.7, 145.1, 145.2, 151.0, 151.5, 152.0, 162.4, 162.6, 187.4,
188.0
5-(2-Iodo-2-tosylacetyl)-2'-deoxyuridine (56). Method A. (β-Keto)sulfone analogue 51
(18 mg, 0.042 mmol) was dissolved in 1 mL MeOH. Then, NaOH(aq) (8.4 µL, 1.68 mg,
0.042 mmol) was added into the solution and was stirred for 30 min. Later, iodine
monochloride (42 µL, 6.18 mg, 0.042 mmol) was added into solution and the resulting
mixtures were stirred for 3 h . The solution was neutralized by adding dil. HCl and volatiles
were evaporated. The residue was column chromatographed (CHCl3/ MeOH; 100:0 → 95:5)
to afford 56 as a (50/50) mixture of diastereomers (8 mg, 35%). 1H NMR (DMSO-d6) δ 2.082.30 (m, 2H, H2'2"), 2.40 (s, 3H, Me), 3.55-3.75 (m, 2H, H5',5"), 3.85 (q, J = 3.4 Hz, 1H,
H4'), 4.22 (m, 1H, H3'), 5.13 (t, J = 4.6 Hz, 0.5H, 5'OH), 5.17 (t, J = 4.5 Hz, 0.5H, 5'OH),
5.28 (d, J = 4.4 Hz, 0.5H, 3'OH), 5.31 (d, J = 4.6 Hz, 0.5H, 3'OH), 5.58-6.10 (m, 1H, H1'),
7.30 (s, 1H, α-CH), 7.45 (d, J = 8.1 Hz, 2H, Ar), 7.75 (d, J = 8.1 Hz, 2H, Ar), 8.80 (s, 0.5H,
H6), 8.82 (s, 0.5H, H6), 11.90 (s, 1H, NH);

13

C NMR (DMSO-d6) δ 21.1, , 40.5, 41.0, 60.8,

60.9, 68.9, 69.9, 70.0, 86.3, 86.5, 88.0, 88.1, 107.7, 107.9, 128.5, 129.5, 129.6, 129.7, 129.8,
133.3, 133.4, 134.5, 134.6, 145.0, 145.2, 150.0, 150.2, 161.0, 161.1, 186.5
Method B. (β-Keto)sulfone 51 (40 mg, 0.094 mmol) was taken in a round bottom flask
containing 0.3 mL of acetic acid. Then iodine (15 mg, 0.056 mmol) and 50% H2O2(aq) (60
μL, 0.94 mmol) were sequentially added into the flask. The resulting mixtures were stirred for
1 h at ambient temperature. The volatiles were evaporated and column chromatography
(CHCl3/ MeOH; 100:0 → 95:5) afforded 5-(α-iodo-β-keto)sulfone 56 ( 21 mg, 41%).
5-(2-Propanethio-2-tosylacetyl)-2'-deoxyuridine (57). The 5-(α-iodo-β-keto)sulfone 56
(10 mg, 0.018 mmol) was dissolved in 1 mL of MeOH. Then 1:1 mixture of propanethiol and
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TEA(8.5 µL, 6.8 mg, 0.076 mmol) was added into a stirring solution of 56 at ambient
temperature for 24 h. The volatiles were evaporated and column chromatography (CHCl3/
MeOH; 100:0 → 95:5) afforded 57 as a (50/50) mixture of diastereomers (2 mg, 22%). 1H
NMR (DMSO-d6) δ 2.08-2.30 (m, 2H, H2'2"), 2.40 (s, 3H, Me), 3.55-3.75 (m, 2H, H5',5"),
3.85 (q, J = 3.4 Hz, 1H, H4'), 4.22 (m, 1H, H3'), 5.13 (t, J = 4.6 Hz, 0.5H, 5'OH), 5.17 (t, J =
4.5 Hz, 0.5H, 5'OH), 5.28 (d, J = 4.4 Hz, 0.5H, 3'OH), 5.31 (d, J = 4.6 Hz, 0.5H, 3'OH), 5.586.10 (m, 1H, H1'), 7.30 (s, 1H, α-CH), 7.45 (d, J = 8.1 Hz, 2H, Ar), 7.75 (d, J = 8.1 Hz, 2H,
Ar), 8.80 (s, 0.5H, H6), 8.82 (s, 0.5H, H6), 11.90 (s, 1H, NH)
8-(1-Chloro-2-tosylvinyl)adenine (67). Treatment of 8-ethynyl adenosine analogue 66
(100 mg, 0.198 mmol) with p-toluenesulfonyl hydrazide (110.6 mg, 0.594 mmol) in the
presence of FeCl3·6H2O (108 mg, 0.396 mmol) by procedure A (column chromatography;
CHCl3/MeOH; 100:0 → 95:5) gave 67 (30 mg, 44%):) 1H NMR (DMSO-d6) δ 2.40 (s, 3H),
7.45 (d, J = 7.9 Hz, 2H), 7.49 (bs, 2H), 7.81(d, J = 8.2 Hz, 2H), 7.88 (s, 1H), 8.18 (s, 1H),
13.6 (s, 1H);

C NMR (DMSO-d6) δ 21.2, 119.4, 128.1, 129.8, 135.2, 136.4, 139.6, 145.0,

13

149.0, 150.7, 153.0, 156.2.
3',5'-Bis-(O-tert-butyldimetylsilyl)-8-(1-iodo-2-tosylvinyl)-2'-deoxyadenosine

(68).

TBDMS protected 8 ethynyl 2'-deoxyadenosine 66 (200 mg, 0.4 mmol) was dissolved in
CH3CN. Then, sodium salt of p-toluenesulfinic acid (205.6 mg, 1.2 mmol) , iodine (152.0 mg,
0.60mmol), and sodium acetate (49.2 mg, 0.6 mmol) were sequentially added into the
solution. The resulting mixtures were stirred at 80oC for 5 h. The volatiles was evaporated and
column chromatography (Hexane/EA; 70:30 → 50:50) gave 68 (148 mg, 48%) as pale yellow
solid. 1H NMR (CDCl3) δ 0.10 (s, 6H), 0.15 (s, 6H), 0.80 (s, 9H), 0.90 (s, 9H), 2.30-2.35 (m,
1H), 2.40 (s, 3H), 3.45-3.55 (m, 1H), 3.80 (bs, 1H), 4.00- 4.10 (m, 2H), 4.85 (bs, 1H), 5.85 (s,
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2H), 6.20 (dd, J = 13.5, 6.7 Hz, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.58 (s,1H), 7.68 (bs, 2H), 8.32
(s, 1H); 13C NMR (CDCl3) δ -0.6, -0.5,-0.4, -0.3, 18.0, 18.5, 22.0, 26.0, 38.0, 63.0, 73.0, 86.0,
88.0, 120, 128.3, 130.0, 136.0, 146.0, 147.5, 150.0, 153.0, 156.0.
S-[(E)-1-(2'-Deoxyuridin-5-yl)-2-tosylvinyl]-L-glutathione monophosphate (72).
The 5'-monophosphate 69 (12 mg, 0.022 mmol) was added in 1 mL of methanol-water (50:50)
co-solvent system. Then, L-glutathione (8.9 mg, 0.029 mmol) and triethylamine (25.0 μL,
17.8 mg, 0.176 mmol) were sequentially added into the solution. The resulting mixtures were
stirred at ambient temperature for 4 h. The volatiles were evaporated and sephadex column
separation (TEAB buffer 0.1-0.3M) gave 72 (10 mg, 57%) as white solid. 1H NMR (D2O) δ
2.15 (q, J = 7.4 Hz, 2H), 2.28-2.41 (m, 2H), 2.44 (s, 3H), 2.52 (dt, J = 15.5, 7.5 Hz, 2H),
3.32-3.38 (m, 1H), 3.70-3.90 (m, 5H), 4.05 (q, J = 3.9 Hz, 1H), 4.45(br, 1H), 4.65-4.72 (m,
2H), 6.30 (t, J = 6.4 Hz, 1H), 6.95 (s, 1H), 7.42 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 8.0 Hz, 2H),
7.95 (s, 1H); 13C NMR (D2O) δ 20.8, 26.2, 31.5, 33.5, 39.5, 42.5, 52.0, 54.0, 59.0, 64.0, 85.0,
86.0, 108.7, 127.0, 130.0, 133.0, 136.0, 142.0, 146.3, 150.6, 161.8, 170.7, 174.0, 175.0, 176.2;
P NMR (D2O) δ 3.75; HRMS calculated for C28H35N5NaO13S2 [M+Na]+ 736.1570, found

31

736.1513
General procedure for the phosphorylation of 5-(β-chloro)vinyl and 5-(βketo)sulfone of 2'-deoxyuridne, synthesis of 5'-triphosphates (71 and 74). Procedure F.
The 5-(β-Chloro)vinyl sulfone 9 or 5-(β-keto)sulfone 51 and proton sponge were placed in a
flame dry round bottom flask. 1 mL trimethyl phosphate was added into the flask and the
mixtures were allowed to cool at 0 oC for 5 min. POCl3 was added and the mixtures were
stirred for 30 min. at 0 oC. Then TBAPP 0.5M solution in DMF and tributylamine were added
sequentially and the resulting mixtures were stirred for 10 min at 0 oC. The reactions were
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quenched by dropwise adding 2M TEAB buffer. The reaction mixtures were extracted with
ethylacetate two times and the aqueous layer was collected. The volatiles were evaporated and
the residue was column chromatographed using Sephadex as adsorbent and TEAB buffer as
eluting solovent to afford product 71 or 74.
(E)-5-(1-Chloro-2-tosylvinyl)-2'-deoxyuridine

triphosphate

(71).

Treatment

of

chlorovinyl sulfone 28 (30 mg, 0.067 mmol) solution in 0.5 mL PO(OMe)3 with POCl3 (16
μL, 26.2 mg, 0.17 mmol) in the presence of proton sponge (37 mg, 0.172 mmol) and
subsequent treatment of the mixtures with 0.5 M TBAPP solution (700 μL, 192 mg, 0.35
mmol) and TBA (50 μL, 39 mg, 0.21 mmol) by procedure F and column chromatography
(TEAB buffer; 0.1M → 0.5M) afforded 5'-triphosphate 71 (15 mg, 32%). 1H NMR (D2O) δ
2.28-2.40 (m, 2H, H2',2"), 2.45 (s, 3H, CH3), 4.14-4.20 (m, 2H, H5',5"), 4.15-4.28 (m, 1H,
H4'), 4.62 (dd, J = 5.7, 2.9 Hz, H3'), 6.28 (t, J = 6.7 Hz, 1H, H1'), 7.44 (d, J = 8.0 Hz, 2H, Ar),
7.45 (s, 1H, vinyl), 7.65 (d, J = 8.2 Hz, 2H, Ar), 8.20 (s, 1H, H6);

13

C NMR (D2O) δ 21.0,

39.0, 66.0, 71.0, 85.0, 86.0, 108.5, 128.0, 130.5, 135.0, 136.0, 141.0, 142.5, 146.0, 150.0,
161.0;

31

P NMR (D2O) δ -23.00 (β-P), -11.50 (α-P), -10.50 (γ-P); HRMS calcd for

C18H21ClN2O6P3S [M-H]-680.9513, found 680.9517
Note: Treatment of the crude product of the reaction between 9 and POCl3 with 2M TEAB
buffer and column chromatography using Sephadex as adsorbent and TEAB buffer as eluting
system (0.1M → 0.25 M) gave 5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine phosphate 69.
5-(2-Tosylacetyl)-2'-deoxyuridine triphosphate (74). Treatmento of β-keto sulfone
analogue 51 (20 mg, 0.047 mmol) solution in 0.5 mL PO(OMe)3 with POCl3 (10 μL, 16.4
mg, 0.107 mmol) in the presence of proton sponge (21 mg, 0.097 mmol) and subsequent
treatment of the mixtures with 0.M TBAPP solution (400 μL, 110 mg, 0.2 mmol) and TBA
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(28 μL, 22 mg, 0.118 mmol) by procedure F and column chromatography (TEAB buffer;
0.1M → 0.5M) afforded desired 5'-triphosphate 74 (12 mg, 38%). 1H NMR (D2O) δ 2.35-2.48
(m, 2H, H2',2"), 2.45 (s, 3H, CH3), 3.58-3.68 (m, 2H, H5',5"), 4.21 (dd, J = 5.6, 4.0 Hz, 2H, αCH2), 4.28 (br, 1H, H4'), 4.62 (dd, J = 6.0, 2.8 Hz, H3'), 6.13 (t, J = 6.4 Hz, 1H, H1'), 7.47 (d,
J = 8.0 Hz, 2H, Ar), 7.65 (d, J = 8.0 Hz, 2H, Ar), 8.46 (s, 1H, H6);

13

C NMR (D2O) δ 21.0,

39.0, 59.0, 65.0, 71.0, 87.0, 88.0, 112.0, 128.0, 130.5, 134.0, 148.0, 149.0, 150.0, 161.0,
185.0;

31

P NMR (D2O) δ -23.50 (β-P), -11.70 (α-P), -11.00 (γ-P); HRMS calcd for

C18H22N2O17P3S [M-H]- 662.9852, found 680.9859
General

procedure

for

esterification

of

5-(β-chloro)vinyl

sulfone

and

5-

heteroarlyated compounds. Synthesis of liphophilic analogues (75-76 and 82-85).
Procedure G. 5-(β-Chloro)vinyl sulfone or 5-arlyated compound was dissolved in 1 mL
DMF. Undecanoic anhydride and DMAP were sequentially added into the solution and stirred
at ambient temperature. The volatiles were evaporated and the residue was partitioned
between CH2Cl2 and 0.1 M HCl/H2O. The organic layer was washed with NaHCO3/H2O and
brine and was column chromatographed to afford (75-76 and 82-85).
(E)-5'-O-Undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (75). Treatment of 5(β-chloro)vinyl sulfone 9 (25 mg, 0.056 mmol) with undecanoic anhydride (24 mg, 0.067
mmol) and DMAP (6.0 mg, 0.05 mmol) in DMF at ambient temperature for 2 h by Procedure
G and column chromatography (hexane/EtOAc, 90:10 → 60:40) afforded 75 (15 mg, 45%):
1

H NMR δ 0.88 (t, J = 6.6 Hz, 3H, CH3), 1.24-1.39 (m, 14H, 7 x CH2), 1.62 ("quin", J = 7.4

Hz, 2H, CH2), 2.10-2.18 (m, 1H, H2'), 2.34 (t, J = 7.7 Hz, 2H, CH2), 2.42 (s, 3H, CH3), 2.49
(ddd, J =13.8, 6.3, 4.0 Hz, 1H, H2''), 3.00 (br s, 1H, 3'-OH), 4.17-4.40 (m, 4H, H3',4',5',5"),
6.26 (t, J = 6.5 Hz, 1H, H1'), 6.85 (s, 1H, CH), 7.35 (d, J = 8.1 Hz, 2H, Ar), 7.74 (d, J = 8.1

100

Hz, 2H, Ar), 8.33 (s, 1H, H6), 8.44 (s, 1H, NH);

13

C NMR δ 14.2, 21.9 (CH3), 22.0, 25.0,

29.2, 29.4, 29.5, 29.7, 29.8, 32.2, 34.4 (CH2), 40.8 (C2'), 63.7 (C5'), 71.6 (C3'), 84.7 (C4'),
85.8 (C1'), 108.2 (C5), 128.0 (Ar), 130.3 (Ar), 134.0 (Ar), 136.0 (=CH), 140.8 (Ar), 143.0
(=CCl), 146.0 (C6), 149.3 (C2), 159.0 (C4), 174.0 (C=O); HRMS calcd for
C29H3935ClN2NaO8S [M+Na]+ 633.2013, found 633.2018.
Note: The (E)-3'-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (7 mg, 20%)
were also isolated: 1H NMR (CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H, CH3), 1.22 -1.37 (m, 14H, 7 x
CH2), 1.58 -1.68 (m, 2H, CH2), 2.35 (t, J = 7.6 Hz, 2H, CH2), 2.38 -2.42 (m, 1H, H2'), 2.44 (s,
3H, CH3-tosyl), 2.5 -2.58 (m, 1H, H2"), 3.89 -3.94 (dd, 1H, H5'), 4.01 -4.06 (dd, 1H, H5"),
4.15 -4.19 (m, 1H, H4'), 5.38 -5.42 (dd, 1H, H3'), 6.34 -6.38 (dd, 1H, H1'), 6.87 (s, 1H,
vinyl), 7.34 (d, J = 8.1 Hz, 2H-tosyl), 7.70 (d, J = 8.1 Hz, 2H-tosyl), 8.34 (s, 1H, H6), 8.44
(s,1H, NH).
(E)-3',5'-Di-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (76). Treatment of
(25 mg, 0.056 mmol) with undecanoic anhydride (62 mg, 0.17 mmol) and DMAP (6.0 mg,
0.05 mmol) in DMF for 6 h by Procedure G and column chromatography (hexane/EtOAc,
100:0 → 80:20) gave 76 (32 mg, 75%): 1H NMR δ 0.84-0.90 (m, 6H, 2 x CH3), 1.20-1.37 (m,
28H, 14 x CH2), 1.60-1.68 (m, 4H, 2 x CH2), 2.35 ("t", J = 8.2 Hz, 4H, 2 x CH2), 2.38-2.42
(m, 1H, H2'), 2.46 (s, 3H, CH3), 2.57 (ddd, J = 12.8, 5.4, 2.1 Hz, 1H, H2"), 4.29-4.32 (m, 1H,
H4'), 4.42 (dd, J = 12.1, 2.4 Hz, 1H, H5'), 4.50 (dd, J = 12.1, 2.3 Hz, 1H, H5"), 5.23-5.27 (m,
1H, H3'), 6.35(dd, J = 8.5, 5.5 Hz, 1H, H1'), 6.88 (s, 1H, vinyl), 7.34 (d, J = 8.1 Hz, 2H, Ar),
7.70 (d, J = 8.1 Hz, 2H, Ar), 7.90 (s, 1H, H6), 8.34 (s, 1H, NH); 13C NMR δ 14.2, 21.8 (CH3),
22.8, 24.9, 25.0, 29.3, 29.37, 29.43, 29.5, 29.58, 29.63, 29.69, 29.72, 32.0, 34.2, 34.3 (CH2),
38.2 (C2'), 63.8 (C5'), 74.2 (C3'), 83.3 (C4'), 85.8 (C1'), 109.1 (C5), 128.0 (Ar), 130.2 (Ar),
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134.9 (=CH), 136.9 (Ar), 139.9 (Ar), 141.6 (C6), 145.6 (=CCl), 149.1 (C2), 158.6 (C4),
173.3, 173.4 (C=O); HRMS calcd for C40H5935ClN2NaO9S [M+Na]+ 801.3527, found
801.3505.
3',5'-Di-O-acetyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (79). 2121 (150 mg, 0.34 mmol)
was dissolved in 2 mL of DMF. 2-Heptylfuran (0.6 mL, 565 mg, 3.4 mmol), TBAF (2.3 mL,
2.38 mmol), and Pd2(dba)3 (12 mg, 0.021 mmol) were sequentially added into the solution.
The resulting mixtures were stirred at 100 oC for 1 h. The volátiles were evapórated and
column chromatography; hexane/EtOAc, 80:20 → 60:40 gave 79 (86 mg, 60%): 1H NMR δ
0.87 (t, J = 7.1 Hz, 3H, CH3), 1.22-1.37 (m, 8H, 4 x CH2), 1.61 (q, J = 7.4 Hz, 2H, CH2), 2.11
(s, 3H, CH3), 2.12 (s, 3H, CH3), 2.25 ("ddd", J = 16.6, 8.7, 2.2 Hz, 1H, H2'), 2.50-2.57 (m,
1H, H2"), 2.59 (t, J = 7.5 Hz, 2H, CH2), 4.30-4.34 (m, 1H, H4'), 4.38-4.42 (m, 2H, H5',5"),
5.28 ("dt", J = 6.4, 1.6 Hz, 1H, H3'), 6.05 (d, J = 3.3 Hz, 1H, furan), 6.40 (dd, J = 8.6, 5.5 Hz,
1H, H1'), 6.98 (d, J = 3.3 Hz, 1H, furan), 7.85 (s, 1H, H6), 9.30 (s, 1H, NH); 13C NMR δ 14.2
(CH3), 20.9, 21.1 (Ac), 22.8, 28.1, 28.2, 29.2, 29.3, 31.9 (CH2), 38.1(C2'), 61.2 (C5'), 74.7
(C3'), 82.7 (C4'), 85.7 (C1'), 107.4 (furan), 108.2 (C5), 111.0 (furan), 131.3 (C6), 143.8, 149.4
(furan), 156.2 (C2), 159.9 (C4), 170.3, 170.5 (Ac); HRMS calcd for C24H32N2NaO8 [M+Na]+
499.2056, found 499.2078.
5-(5-Heptylfur-2-yl)-2'-deoxyuridine (81). 5-Iodo-2'-deoxyuridine 77 (53 mg, 0.15
mmol) was dissolved in 2 mL DMF. Then, 2-heptylfuran (0.29 mL, 249 mg, 1.5 mmol),
TBAF (1 mL, 1.05 mmol), Pd2(dba)3 (10 mg, 0.017 mmol) were sequentially added into the
solution. The mixtures were stirred at 100 oC for 1 h. The volatiles were evaporated and
column chromatography (hexane/EtOAc, 20:80) gave 81 (35 mg, 61%): UV (MeOH) λmax
256, 326 nm (ε 14 250, 11 300), λmin 287 nm (ε 4000); 1H NMR (DMSO-d6) δ 0.86 (t, J =6.7
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Hz, 3H, CH3), 1.24-1.31 (m, 8H, 4 x CH2), 1.60 (quin, J = 6.7 Hz, 2H, heptyl), 2.17 ("dd", J =
6.6, 4.9 Hz, 2H, H2',2''), 2.60 (t, J = 7.4 Hz, 2H, CH2), 3.60-3.62 (m, 2H, H5',5''), 3.83 (q, J =
3.3 Hz, 1H, H4'), 4.29 (quin, J = 4.2, 1H, H3'), 5.05 (t, J = 5.0 Hz, 1H, 5'-OH), 5.28 (d, J = 4.1
Hz, 1H, 3'-OH), 6.11 (d, J = 3.1 Hz, 1H, furan), 6.21 (t, J = 6.6 Hz, 1H, H1'), 6.72 (d, J = 3.1
Hz, 1H, furan), 8.27 (s, 1H, H6), 11.58 (s, 1H, NH); 13C NMR δ 14.2, 22.1, 27.0, 28.6, 31.1,
39.4, 60.8, 70.3, 84.5, 87.4, 105.7, 106.8, 108.6, 133.6, 144.5, 149.6, 154.8, 160.0; HRMS
calcd for C20H29N2O6 [M+H]+ 393.2020, found 393.2023
5'-O-Undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (82). Treatment of 80122 (25 mg, 0.08
mmol) with undecanoic anhydride (34 mg, 0.096 mmol) in the presence of DMAP (6.0 mg,
0.05 mmol) in DMF for 2 h by Procedure G and column chromatography; hexane/EtOAc,
100:0 → 70:30) gave 82 (18 mg, 52%) and 83 (5 mg, 10%) in addition to unchanged 80
(~15%; TLC). Compound 82 had: 1H NMR δ 0.88 (t, J = 7.1 Hz, 3H, CH3), 1.22-1.40 (m,
14H, 7 x CH2), 1.60 ("quin", J = 7.3 Hz, 2H, CH2), 2.10-2.17 (m, 1H, H2'), 2.35 (t, J = 7.6 Hz,
2H, CH2), 2.50 (ddd, J =13.7, 6.3, 3.9 Hz, 1H, H2''), 3.05 (br s, 1H, 3'-OH), 4.15 (q, J = 3.9,
1H, H4'), 4.25 (dd, J = 12.1, 3.3 Hz, 1H, H5'), 4.36-4.42 (m, 2H, H3',5"), 6.26 (t, J = 6.3 Hz,
1H, H1'), 6.60 (dd, J = 3.3, 1.8 Hz, 1H, furan), 7.05 (d, J = 3.5 Hz, 1H, furan), 7.38 (d, J = 1.2
Hz, 1H, furan), 8.25 (s, 1H, H6), 8.38 (s, 1H, NH); HRMS calcd for C24H34N2NaO7 [M+Na]+
485.2264; found 485.2271.
Note: 3'-O-Undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (6.0 mg, 15%) was also isolated: 1H
NMR (CDCl3) δ 0.85-0.93 (m, 6H, 2 x CH3), 1.22 -1.37 (m, 24H, 12 x CH2), 1.58 -1.68 (m,
4H, 2 x CH2), 2.35 (t, J = 7.6 Hz, 2H, CH2- undecanoyl), 2.45 (dt, 1H, H2'), 2.55 (dt, 1H,
H2"), 2.64 (t, 2H, J = 7.6 Hz, CH2- heptyl), 3.90 - 4.00 (dd, 1H, H5'5"), 4.13 -4.18 (m, 1H,
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H4'), 5.38 -5.42 (dd, 1H, H3'), 6.05 (d, , J = 3.2 Hz, 1H-furan), 6.29 -6.35 (dd, 1H, H1'), 6.90
(d, J = 3.2 Hz, 1H-furan), 8.10 (s, 1H, H6), 8.44 (s,1H, NH).
3',5'-Di-O-undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (83). Treatment of 80122 (25 mg,
0.08 mmol) with undecanoic anhydride (84 mg, 0.24 mmol) in the presence of DMAP (6.0
mg, 0.05 mmol) by Procedure G (6 h) gave 83 (38.5 mg, 77%): 1H NMR δ 0.82-0.91 (m, 6H,
2 x CH3), 1.20-1.40 (m, 28H, 14 x CH2), 1.60-1.68 (m, 4H, 2 x CH2), 2.24 (ddd, J = 14.6, 8.6,
6.5 Hz, 1H, H2'), 2.33-2.40 (m, 4H, 2 x CH2), 2.54 (ddd, J = 14.1, 5.6, 1.3 Hz, 1H, H2"), 4.30
("q", J = 2.7 Hz, 1H, H4'), 4.36 (dd, J = 12.2, 2.8 Hz, 1H, H5'), 4.45 (dd, J =11.8, 3.5 Hz, 1H,
H5"), 5.27 ("dt", J = 6.4, 1.6 Hz, 1H, H3'), 6.40 (dd, J = 8.8, 6.1 Hz, 1H, H1'), 6.47 (dd, J =
3.3, 1.8 Hz, 1H, furan), 7.05 (d, J = 3.4 Hz, 1H, furan), 7.33 (d, J = 1.6 Hz, 1H, furan), 8.00
(s, 1H, H6), 8.95 (s, 1H, NH); 13C NMR δ 14.5, 23.0, 25.1, 25.2, 29.3, 29.4, 29.6, 29.7, 29.9,
32.3, 34.1, 34.3, 34.5, 39.0 (C2'), 64.0 (C5'), 74.6 (C3'), 83.2 (C4'), 86.0 (C1'), 108.0 (C5),
110.0 (furan), 112.5 (furan), 133.0 (C6), 142.0 (furan), 146.0 (furan), 149.5 (C2), 160.2 (C4),
173.2, 173.4 (C=O); HRMS calcd for C35H54N2NaO8 [M+Na]+ 653.3778, found 653.3778.
5'-O-Undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (84). Treatment of 81 (25 mg,
0.064 mmol) with undecanoic anhydride (27.2 mg, 0.0768 mmol) in the presence of DMAP
(6.0 mg, 0.05 mmol) for 2 h and column chromatography (hexane/EtOAc, 100:0 → 80:20)
gave 84(17 mg, 48%). 1H NMR δ 0.85-0.90 (m, 6H, 2 x CH3), 1.28-1.31 (m, 22H, 11 x CH2),
1.54-1.64 (m, 4H, 2 x CH2), 2.13-2.16 (m, 1H, H2'), 2.27-2.32 (m, 2H, CH2), 2.46 (ddd, J
=13.9, 6.4, 4.3 Hz, 1H, H2''), 2.56 (t, J = 7.4 Hz, 2H, CH2), 2.98 (s, 1H, 3'-OH), 4.19 (q, J =
3.5, 1H, H4'), 4.28 (dd, J = 12.3, 3.4 Hz, 1H, H5'), 4.33-4.41 (m, 2H, H3',5"), 6.05 (d, J = 3.2
Hz, 1H-furan), 6.28 (t, J = 6.4 Hz, 1H, H1'), 6.90 (d, J = 3.2 Hz, 1H-furan), 8.10 (s, 1H, H6),
8.44 (s,1H, NH);

13

C NMR δ 14.2, 22.9 (CH3), 24.9, 28.1, 28.2, 29.2, 29.2, 29.3, 29.4, 29.5,
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29.6, 29.7, 31.9, 32.1, 34.2, 34.3, 34.4 (CH2), 40.7 (C2'), 63.6 (C5'), 71.8 (C3'), 84.4 (C4'),
85.5 (C1'), 108.2 (C5), 110.6 (furan), 113.0 (furan), 129.0 (furan), 133.0 (C6), 149 (C2), 156.0
(furan), 159.6 (C4), 174.0 (C=O); HRMS calcd for C31H48N2NaO7 [M+Na]+ 583.3359, found
583.3375.
Note: 3'-O-undecanoyl-5-(heptylfur-2-yl)-2'-deoxyuridine (6.1 mg, 17%) was also
isolated: 1H NMR (CDCl3) δ 0.88 (t, J = 7.1 Hz, 3H, CH3), 1.22 -1.40 (m, 14H, 7 x CH2), 1.60
-1.65 (m, 2H, CH2), 2.35 (t, J = 7.6 Hz, 2H, CH2), 2.44 -2.58 (m, 2H, H2'), 4.0 (dd, 2H, H5'),
4.15(m, 1H, H4'), 5.40 (dd, 1H, H3'), 6.35 (dd, 1H, H1'), 6.6 (dd, 1H, furan), 7.05 (d, J = 3.5
Hz, 1H, furan), 7.38 (d, J = 1.2 Hz, 1H, furan), 7.34 (d, J = 8.1 Hz, 2H-tosyl), 8.25 (s, 1H,
H6), 8.38 (s, 1H, NH).
3',5'-Di-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (85). Treatment of 81 (25
mg, 0.064 mmol) with undecanoic anhydride (65 mg, 0.19 mmol) in the presence of DMAP
(6.0 mg, 0.05 mmol) for 6 h and column chromatography (hexane/EtOAc, 100:0 → 80:20)
gave 85 (36 mg, 80%). 1H NMR δ 0.83-0.92 (m, 9H, 3 x CH3), 1.22-1.38 (m, 36H, 18 x CH2),
1.55-1.70 (m, 6H, 3 x CH2), 2.25 (ddd, J = 14.7, 8.5, 6.6 Hz, 1H, H2'), 2.30-2.40 (m, 4H, 2 x
CH2), 2.53-2.57 (m, 1H, H2"), 2.60 (t, J = 7.6 Hz, 2H, CH2), 4.31 (q, J = 3.0 1H, H4'), 4.38
(dd, J = 12.2, 2.8 Hz, 1H, H5'), 4.42 (dd, J =11.3, 3.8 Hz, 1H, H5"), 5.26 ("dt", J = 6.8, 1.6
Hz, 1H, H3'), 6.05 (d, J = 3.2 Hz, 1H, furan), 6.37 (dd, J = 8.8, 6.1 Hz, 1H, H1'), 6.95 (d, J =
3.3 Hz, 1H, furan), 7.88 (s, 1H, H6), 9.00 (s, 1H, NH); HRMS calcd for C42H68N2NaO8
[M+Na]+ 751.4873, found 751.4851.
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4.3. Incorporation of 5-modified nucleotides into DNA
Materials of enzymatic reactions
All DNA oligonucleotides were synthesized following the Integrated DNA Technologies
(Coralville, IA). The radionucleotides -32P] ATP (6000 mCi/mmol) was purchased from MP
biomedicals Inc. (Santa Ana, CA) while T4 polynucleotide kinase and deoxynucleoside 5’triphosphates (dNTPs) were purchased from Thermo Scientific (Pittsburgh, PA). Micro BioSpin TM 6 Columns were purchased from Bio-Rad (Hercules, CA). All other chemicals were
purchased from Thermo Scientific (Pittsburgh, PA) and Sigma-Aldrich (St. Louis, MO).
Purified DNA polymerase β (pol β) were purified following the procedures described
previously.123,124 Klenow fragment was bought from New England Biolabs (Ipswitch, MA).
Oligonucleotide substrates
Substrates with an upstream primer annealed to the template strand were designated as
open template substrates. The substrates were made by annealing upstream primer (31nt) with
the template strand (71 nt) at a molar ratio of 1:3. The substrate containing one-nucleotide gap
were made by annealing an upstream primer and downstream primer with the template strand
at the molar ratio of 1:3:3. The open template and one-nucleotide gap substrates were
employed to mimic the intermediates formed during DNA replication.
Enzymatic activity assay
Nucleotides incorporation by DNA polymerases were performed by incubating different
concentrations of pol β or Klenow fragment with 25 nM 32P labeled substrates at 37°C for 15
min. The enzymatic reactions were assembled in the presence of 5-(β-chlorovinyl)sulfone of
dU (50 μM) or 5-(β-keto)sulfone of dU (50 μM) alone or in the presence of 50 μM 5-(βchlorovinyl)sulfone of dU or 50 μM 5-(β-keto)sulfone of dU along with 50 μM dATP, 50 μM
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dCTP and 50 μM dGTP. This allows to examine if 5-(β-chlorovinyl)sulfone of dU or 5-(βketo)sulfone of dU residue can be directly incorporated into a double-strand DNA during
DNA leading and lagging strand maturation. DNA synthesis was separated in a 15% urea
denaturing polyacrylamide gel were detected by Pharos FX Plus PhosphorImager (Bio-Rad
Laboratory, CA).
4.4. Cytotoxic evaluation
Proliferation Assays
Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 cells/well
in the presence of 5-fold dilutions of the compounds. After 4 days of incubation, the cells
were trypsinized and counted by means of a Coulter counter (Analis, Belgium). Suspension
cells (Mouse leukemia L1210 and human lymphoid CEM cells) were seeded in 96-well plates
at 60,000 cells/well in the presence of the compounds. L1210 and CEM cells were allowed to
proliferate for 48 h or 96 h, respectively and then counted. The 50% inhibitory concentration
(IC50) was defined as the compound concentration required to reduce cell proliferation by
50%.
Antiviral Assays
The compounds were evaluated against the following viruses: herpes simplex virus type 1
(HSV-1) strain KOS, thymidine kinase-deficient (TK-) HSV-1 KOS strain resistant to ACV
(ACVr), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster virus (VZV) strain
Oka, TK- VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis,
vaccinia virus Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular
stomatitis virus (VSV), Coxsackie B4, parainfluenza 3, influenza virus A (subtypes H1N1,
H3N2), influenza virus B, Sindbis, reovirus-1, Punta Toro, human immunodeficiency virus
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type 1 strain IIIB and human immunodeficiency virus type 2 strain ROD. The antiviral, other
than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or plaque
formation in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero),
human epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). Confluent cell
cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50
being the virus dose to infect 50% of the cell cultures) or with 20 or 100 plaque forming units
(PFU) (VZV or HCMV) in the presence of varying concentrations of the test compounds.
Viral cytopathicity or plaque formation was recorded as soon as it reached completion in the
control virus-infected cell cultures that were not treated with the test compounds. Antiviral
activity was expressed as the EC50 or compound concentration required to reduce virusinduced cytopathogenicity or viral plaque formation by 50%. Cytotoxicity of the test
compounds was expressed as the minimum cytotoxic concentration (MCC) or the compound
concentration that caused a microscopically detectable alteration of cell morphology
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5. CONCLUSION
I have successfully synthesized 5-(1-chloro/bromo-2-tosylvinyl)pyrimidine nucleosides
from their corresponding 5-ethynyl analogues via transition metal catalyzed halosulfonylation
reaction with moderate to excellent yield (45-90%). The 5-(1-iodo-2-tosylvinyl)pyrimidine
nucleosides analogues were obtained via halosulfonylation reaction by reaction of 5-ethynyl
pyrimidine nucleoside analogue with sodium salt of p-toluenesulfinic acid and Niodosuccinamide in moderate yield (42-50%). The physical, chemical, and biological
properties of these novel 5-(1-halo-2-tosylvinyl)pyrimidine nucleosides analogues were also
explored. It was discovered that unlike the unsubsituted vinyl sulfone, the (β-halo)vinyl
sulfones underwent addition-elimination reaction efficiently with varieties of nucleophiles
such as amines, thiols etc. Although the (β-halo)vinyl sulfones substrates possesses
exclusively E stereochemistry at the vinylic position, their addition-elimination products
possess either E or Z stereochemistry which was found to be dependent on the type of
nucleophiles substitute the halogen atom at the β-position. If the halogen atom is substituted
by the thiolate nucleophile, the addition-elimination reaction occurs with retention of
configuration to give exclusively E stereochemistry. If the same halogen atom of the vinyl
sulfone analogue is replaced by amino nucleophile in the analogous reaction the
stereochemistry of resulting aminovinylsulfones is Z which means that reaction occurs with
the inversion of configuration. From the kinetics data it was determined that the rate of
reaction follows the descending order as I ≥ Br > Cl. That means the rate of additionelimination reaction of novel (β-halo)vinyl sulfone analogues is dependent on the halogen
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atoms attached at the β-position. The vinylic proton exchange with deuterium during the
addition-elimination reaction was investigated by carrying the reaction in different deuterated
solvents such as DMSO-d6, D2O, or MeOH-d4. The cysteine and tripeptide L-glutathione were
incorporated at the β-position of the uracil nucleoside analogues via conjugated additionelimination reaction. Antiproliferative and antivirul properties of the (β-halo)vinyl sulfone
analogues were examined and it was found that acetyl protected (β-chloro)vinyl sulfone
analogue inhibited the growth of the L1210, CEM, and HeLa cancer cells in the lower μM
range. The lipophilic undecanoyl groups were incorporated at the sugar moiety via
esterification reaction to enhance the cell permeability of these analogues but unfortunately
they did not show improved cytostatic activity.
Novel (β-keto)sulfone analogues of 5-modified pyrimidine nucleoside have been
synthesized and their reactivity at the acidic α-carbon were explored. So, 5-(βchloro)vinylsulfones were efficiently converted into the corresponding 5-(β-keto)sulfone
analogues via a one pot synthetic procedure. Thus, (E)-(β-chloro)vinylsulfone analogues were
converted into (Z)-(β-amino)vinylsulfone by treatment with methanolic ammonia. Subsequent
acid hydrolysis efficiently converted the intermediary amino sulfone into β-keto sulfone
analogues with good yield (60-70%). Since the proton at α-carbon of β-keto sulfone is acidic,
novel chemistry at the α-carbon of β-keto sulfones were investigated. The reactivity at the αcarbon of β-keto sulfone analogues with different electrophiles and nucleophiles were
elaborately explored to find a suitable way to incorporate amino acid residues at the α-carbon
which would verify the feasibility of the bioconjugation of the 5-(β-keto)sulfone-modified
DNA with proteins. Different electrophiles derived from benzyl, methyl, or allyl halides were
efficiently incorporated at the α-carbon of β-keto sulfone analogues. In addition, it was
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demonstrated that in two step protocols the α-carbon of β-keto sulfones can be also substituted
by nucleophile. Thus, treatment of 5-(β-keto)sulfone-modified 2'-deoxyuridine with
iodinemonochloride afforded the product with the α-carbon substituted by iodo group.
Subsequently, this iodo group served as a good leaving group and was displaced by the
thiolate in the presence of triethyl amine. Such approach might be extended to incorporate
amino acid possessing active nucleophilic groups at the α-carbon of the β-keto sulfones.
The silyl protected 8-(1-iodo-2-tosylvinyl)-2'-deoxyadenosine was also efficiently
synthesized by the iodine mediated halosulfonylation of the corresponding 8-alkynyl
substrates with the yield of 48%. The success of this reaction was encouraging to extend this
halosulfonylation reaction in future into other purine nucleoside systems.
The 5-(β-chloro)vinylsulfone- or 5-(β-keto)sulfone modified 2'-deoxyuridine were
efficiently converted to the 5'-triphosphates by applying Yoshikawa method followed by
treatment with ammonium pyrophosphate in the presence of tributylamine. These nucleotides
were successfully inserted into the DNA by polymerase-catalyzed reactions with either human
DNA repaired polymerase (pol β) or bacterial polymerase (pol I). The (β-chloro)vinyl sulone
analogue was efficiently incorporated both into the open template that leads the DNA
synthesis and one nucleotide gap template that lags the DNA synthesis via bacterial
polymerase (Pol I) catalyzed reaction. However, the human DNA polymerase (pol β)
catalyzed process was successful to incorporate the chlorovinyl analogue into the one
nucleotide gap template only. The (β-keto) sulfone analogue was efficiently inserted into
DNA open template and one nucleotide gap template either by human DNA repaired
polymerase (pol β) or bacterial polymerase (pol I).
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The 5-(β-chloro)vinyl and/or 5-(β-keto) sulfones might be bioconjugated with the
proteins which are involved in DNA replication process. Specifically it would be interested to
examine whether the (β-chloro)vinyl sulfone modified DNA might bioconjugate with thiol
residues of transcription factors such as c-Myc protein and thus uncover the mystery of
critical biological functions related to DNA-c-Myc protein interactions.
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